

ARTICLE OPEN



Global estimates on the number of people blind or visually impaired by Uncorrected Refractive Error: a meta-analysis from 2000 to 2020

Vision Loss Expert Group of the Global Burden of Disease Study* and the GBD 2019 Blindness and Vision Impairment Collaborators*

© The Author(s) 2024

BACKGROUND: Uncorrected refractive error (URE) is a readily treatable cause of visual impairment (VI). This study provides updated estimates of global and regional vision loss due to URE, presenting temporal change for VISION 2020

METHODS: Data from population-based eye disease surveys from 1980–2018 were collected. Hierarchical models estimated prevalence (95% uncertainty intervals [UI]) of blindness (presenting visual acuity (VA) < 3/60) and moderate-to-severe vision impairment (MSVI; 3/60 ≤ presenting VA < 6/18) caused by URE, stratified by age, sex, region, and year. Near VI prevalence from uncorrected presbyopia was defined as presenting near VA < N6/N8 at 40 cm when best-corrected distance (VA ≥ 6/12).

RESULTS: In 2020, 3.7 million people (95%UI 3.10–4.29) were blind and 157 million (140–176) had MSVI due to URE, a 21.8% increase in blindness and 72.0% increase in MSVI since 2000. Age-standardised prevalence of URE blindness and MSVI decreased by 30.5% (30.7–30.3) and 2.4% (2.6–2.2) respectively during this time. In 2020, South Asia GBD super-region had the highest 50+ years age-standardised URE blindness (0.33% (0.26–0.40%)) and MSVI (10.3% (8.82–12.10%)) rates. The age-standardized ratio of women to men for URE blindness was 1.05:1.00 in 2020 and 1.03:1.00 in 2000. An estimated 419 million (295–562) people 50+ had near VI from uncorrected presbyopia, a +75.3% (74.6–76.0) increase from 2000

CONCLUSIONS: The number of cases of VI from URE substantively grew, even as age-standardised prevalence fell, since 2000, with a continued disproportionate burden by region and sex. Global population ageing will increase this burden, highlighting urgent need for novel approaches to refractive service delivery.

Eye (2024) 38:2083–2101; <https://doi.org/10.1038/s41433-024-03106-0>

INTRODUCTION

Uncorrected refractive error (URE) is the leading cause of vision impairment globally among both adults and children, and contributes to reduced educational and economic opportunities [1–6], decreased quality of life [7] and an increased burden of mortality [8–10]. Visual impairment is a significant global health concern and the financial burden with global productivity losses is estimated to be 411 billion US dollars annually [11]. URE is readily treated with spectacles, making it one of the most cost-effective healthcare interventions, alongside cataract surgery [12–15]. Thus, it is a global priority to improve access to refraction services [11], as set out in ‘Towards universal eye health: Global Action Plan 2014–2019 of the World Health Assembly (WHA) in 2013 [16], and more recently in the ‘World Report on Vision’ by the World Health Organisation (WHO) in 2019 [17], which called for the routine measurement of refractive error services coverage as a means to address the United Nations (UN) Sustainable Development Goals [18] target 3.8 to “achieve universal health coverage, including financial risk protection, access to quality essential healthcare services and access to safe, effective, quality and affordable essential medicines and vaccines for all”. Furthermore, these recommendations have been adopted in a resolution by the 73rd WHA member states in 2021, which set

global targets for a 40% increase in effective refractive error coverage (eREC) by 2030. As we transition from the efforts of VISION 2020: the Right to Sight initiative to tackle avoidable blindness, these focused targets are fundamental to eliminate avoidable vision loss in future.

Refractive error is a common ocular condition which occurs throughout the lifespan [19], and chiefly falls into the following categories: myopia (affecting mostly distance vision), hyperopia (potentially causing impaired vision at distance and near), which may both be accompanied by an astigmatic component, and presbyopia (characterised by poor near vision). The last 20 years have seen rapid increases in the prevalence of myopia across the world, particularly in East Asia [20–23].

Nearly all individuals, even those without significant refractive error in childhood and earlier adult years will acquire presbyopia by the 5th decade of life, necessitating refractive correction for near work. Presbyopia occurs due to reduced flexibility of the human crystalline lens to accommodate (focus) on near targets, resulting in blurred near vision. It is an essentially universal phenomenon, with age of onset determined by factors such as the presence of latent hyperopia. Without refractive correction, vision deteriorates for near activities, resulting in near visual impairment. Where uncorrected hyperopia is common, due to

*Lists of authors and their affiliations appear at the end of the paper.

lack of access to both education (which induces myopia [24]) and refractive services, the onset of presbyopia may even occur in the 30 s, which is a critical working age for those in industries such as garments and textiles [25, 26]. With an ageing global population, the burden of presbyopia and near visual impairment will increase. Coupled with the impact of the increased prevalence of myopia, the burden of URE is likely to grow in the future.

The Vision Loss Expert Group (VLEG) curate a comprehensive, continuously updated, online database of ophthalmic epidemiological data and have made important contributions to knowledge about the burden and causes of vision impairment and blindness globally [27–29]. These estimates have been used in the WHO Report on Vision in 2019 [17] and the recent Lancet Global Health commission on Global Eye Health Report [15]. Updated analyses are required to reflect rapidly increasing sources of new population data, and to monitor progress in reduction of avoidable sight loss. The need for new population data on vision impairment has been emphasised in a recent paper highlighting the grand challenge priorities for global eye health [30], and will be vital to monitor and measure success against the WHA global target of a 40% increase in eREC.

Thus, the aim of the current study is to provide updated estimates of the global burden of vision loss due to URE, disaggregated by sex, age, year and region, for the period from 2000 to 2020 covered by VISION 2020: The Right to Sight initiative. For the first time, temporal trends will be calculated to present the burden of visual impairment resulting from uncorrected presbyopia in those 50+ years.

METHODS

A systematic review of population-based studies of vision impairment and blindness published between Jan 1, 1980, and Oct 1, 2018, was carried out, which included grey literature sources. Eligible studies from this review were then combined with data from Rapid Assessment of Avoidable Blindness (RAAB) studies and finally, data from the US National Health and Nutrition Examination Survey and the WHO Study on Global Ageing and Adult Health were added. More detailed methods are published elsewhere [30, 31], and outlined below.

In total, the VLEG review identified 243 studies (73% were rapid studies) across 73 countries from which data relating to the contribution of URE to vision loss could be extracted: with 70 studies from the 2010 review [28], and a further 173 studies in an extension of the literature review to 2018 [29]. Studies were primarily national and subnational cross-sectional surveys. By the seven World Global Burden of Disease (GBD) super regions, 43 studies were from Sub-Saharan Africa, 100 from Southeast Asia, East Asia, and Oceania, 44 from South Asia, 16 from North Africa and the Middle East, 25 from Latin America and the Caribbean, 9 from High income, and 6 from Central Europe, Eastern Europe, and Central Asia. Additionally, the VLEG commissioned the preparation of 5-year age-disaggregated RAAB data from the RAAB repository. Studies were included if they met the following criteria: visual acuity data had to be measured using a test chart that could be mapped to the Snellen scale, and the sample had to be representative of the population. Studies based on self-report of vision loss were excluded. The International Classification of Diseases 11th edition [32] criteria for vision loss, as suggested by WHO, was employed, categorizing individuals according to vision in their better eye on presentation. This classification defines moderate vision loss as visual acuity of 6/60 or better but less than 6/18, severe vision loss as a visual acuity of 3/60 or better but less than 6/60, and blindness as visual acuity of less than 3/60 or less than 10° visual field around central fixation (although the visual field definition is rarely used in population-based eye surveys). Moderate and severe visual impairment (MSVI) was combined to present prevalence data. Vision impairment from uncorrected presbyopia was defined as presenting near vision of worse than <N6 or <N8 at 40 cm where best-corrected distance visual acuity was 6/12 or better. Prevalence of near VI from uncorrected presbyopia was based on 25 studies.

The global and regional prevalence and burden of blindness and MSVI due to URE were gathered from the all-cause meta-analysis and modelling. First, we separated raw data into datasets including so-called vision loss envelopes (see Flaxman et al. [28] for explanation) for all-cause mild, moderate, and severe vision loss, and blindness. Data were input

into a mixed-effects meta-regression tool developed by the Institute for Health Metrics and Evaluation and called MR-BRT (meta-regression; Bayesian; regularised; trimmed) [33]. Presenting vision impairment was the reference definition for each level of severity. Prevalence data for URE were extracted directly where available and otherwise calculated by subtracting best-corrected vision impairment from presenting vision impairment prevalence for each level of severity in studies that reported both measures for a given location, sex, age group, and year. All other causes were quantified as part of the best-corrected estimates of vision impairment at each level of severity.

We modelled distance vision impairment and blindness attributable to the following causes: cataract, URE, age-related macular degeneration, myopic macular degeneration, glaucoma, diabetic retinopathy, and other causes of vision impairment (in aggregate).

We produced location-, year-, age-, and sex-specific estimates of MSVI and blindness using Disease Modelling Meta-Regression (Dismod-MR) 2.1 [34]. The details of the data processing steps are described elsewhere [29]. Briefly, Dismod-MR 2.1 models were run for all vision impairment stratified by severity (moderate, severe, blindness) regardless of cause and, separately, for MSVI and blindness due to each modelled cause of vision impairment. Then, models of MSVI due to specific causes were split into moderate and severe vision loss estimates using the ratio of overall prevalence in the all-cause moderate presenting vision impairment and severe presenting vision impairment models. Next, prevalence estimates for all causes stratified by severity were scaled to the models of all-cause prevalence by severity. This produced final estimates by age, sex, year, and location for each individual cause of vision impairment stratified by severity, including refractive error. Model projection was to the year 2020, coincident with the end of VISION 2020: the Right to Sight initiative, and estimates were age-standardised using the GBD standard population [35]. All generated estimates for visual impairment due to URE are accompanied by 95% uncertainty intervals (UI), which represent the 25th and 975th ordered estimates of 1000 draw estimates of the posterior distribution. We considered estimates to be significantly different if the 95% UIs did not overlap. Data are presented for the total population and also for individuals aged 50+ years, as data sources such as RAAB surveys are major sources of data for low-income and low- or middle-income countries (LICs and LMICs) and these surveys are conducted on individuals aged 50 years and older. The data estimates reported in this study were produced in compliance with the Guidelines for Accurate and Transparent Health Estimates Reporting [36].

Data are presented for the seven World super-regions based on the GBD regional classification system [37], and sub-divided into the 21 GBD world regions. These seven super regions are drawn together based on two criteria: epidemiological similarity and geographic proximity.

RESULTS

We used 243 data sources from 73 countries to calculate the global and regional prevalence and burden of blindness and MSVI due to URE. Table 1 presents the number of people, men and women, with blindness (<3/60) or MSVI (<6/18 to >=3/60) due to URE in 2020 in the seven super-regions based on the GBD classification system. Appendix 1 contains supplementary tables for all 21 GBD world regions in 2020. These estimates reveal that in 2020, 3.70 million people (95% UI 3.10–4.29 million) in the world were blind and 157 million (95% UI 140–175 million) had MSVI due to URE. Focusing on those 50+ years of age, 2.29 million people (95% UI 1.79–2.80 million) were blind due to URE globally and 86.1 million (95% UI 74.2–101 million) had MSVI.

As a percentage of all types of blindness, the burden of blindness due to URE globally is 8.60% (95% UI 7.22–9.99%) and is greatest for the super regions of South Asia (12.71%, 95% UI 10.58–14.82%) and Southeast Asia, East Asia and Oceania (9.34%, 95% UI 7.67–10.94%). These updated data estimate that URE is the leading cause of MSVI globally, accounting for 53.39% (95% UI 47.56–59.51%) of all cases. Focusing on blindness due to URE in those aged 50+ years, South Asia accounts for the largest age-standardised prevalence (0.33% (95% UI 0.26–0.40%)), followed by the super-regions of Southeast Asia, East Asia and Oceania (0.15% (95% UI 0.12–0.18%)) and Sub-Saharan Africa (0.11% (95% UI 0.09–0.14%)).

Table 1. Number and age-standardised prevalence of people with blindness (<3/60) or MSVI (<6/18 to >=3/60) due to URE in 7 Super Regions in 2020.

	GLOBAL	Central Europe, Eastern Europe, and Central Asia	High income	Latin America and Caribbean	North Africa and Middle East	South Asia	Southeast Asia, East Asia, and Oceania	Sub-Saharan Africa
Total population 2020 (thousands)	7,890,000	417,000	1,090,000	602,000	632,000	1,840,000	2,190,000	1,110,000
Number of people with blindness (thousands)	3700 (3100–4290)	29.4 (23.3–36.0)	80.0 (63.6–97.6)	218 (180–258)	190 (156–229)	1520 (1260–1770)	1410 (1150–1650)	254 (212–303)
Number of Men with blindness (thousands)	1750 (1480–2020)	13.7 (10.8–17.1)	36.9 (29.1–44.8)	96.1 (78.6–114)	90.4 (73.6–109)	728 (606–847)	657 (539–769)	123 (102–146)
Number of Women with blindness (thousands)	1950 (1620–2280)	15.7 (12.4–19.2)	43.1 (34.6–52.3)	122 (101–144)	99.8 (81.8–120)	789 (658–925)	750 (616–879)	132 (110–157)
Number of people with blindness aged 50+ years (thousands)	2290 (1790–2800)	16.8 (12.8–21.1)	46.1 (35.7–56.9)	126 (97.5–153)	84.2 (63.8–103)	976 (762–1190)	933 (728–1140)	111 (84.5–136)
Number of Men with blindness aged 50+ years (thousands)	1050 (816–1270)	7.05 (5.27–8.88)	21.1 (16.2–26.1)	53.8 (41.3–65.7)	39.3 (29.6–48.3)	459 (358–558)	415 (325–509)	52.5 (40.2–65.0)
Number of Women with blindness aged 50+ years (thousands)	1250 (975–1520)	9.76 (7.35–12.4)	25.0 (19.3–30.9)	72.5 (56.4–87.6)	44.9 (34.1–55.3)	517 (402–633)	518 (406–632)	58.2 (44.3–71.9)
Age-standardised prevalence of blindness	0.04% (0.04–0.05)	0.01% (0.00–0.01)	0.01% (0.00–0.01)	0.04% (0.03–0.04)	0.03% (0.03–0.04)	0.10% (0.08–0.12)	0.05% (0.04–0.06)	0.04% (0.03–0.04)
Age-standardised prevalence of blindness: Men	0.04% (0.04–0.05)	0.01% (0.00–0.01)	0.01% (0.00–0.01)	0.03% (0.03–0.04)	0.03% (0.03–0.04)	0.10% (0.08–0.11)	0.05% (0.04–0.06)	0.04% (0.03–0.05)
Age-standardised prevalence of blindness: Women	0.05% (0.04–0.05)	0.01% (0.00–0.01)	0.01% (0.00–0.01)	0.04% (0.03–0.04)	0.04% (0.03–0.04)	0.10% (0.09–0.12)	0.06% (0.05–0.06)	0.04% (0.03–0.04)
Age-standardised prevalence of blindness 50+ years	0.12% (0.10–0.15)	0.01% (0.01–0.02)	0.01% (0.01–0.01)	0.09% (0.07–0.11)	0.09% (0.07–0.11)	0.33% (0.26–0.40)	0.15% (0.12–0.18)	0.11% (0.09–0.14)
Age-standardised prevalence of blindness in Men 50+ years	0.12% (0.09–0.14)	0.01% (0.01–0.02)	0.01% (0.01–0.01)	0.09% (0.07–0.11)	0.08% (0.06–0.10)	0.32% (0.25–0.38)	0.14% (0.11–0.17)	0.12% (0.09–0.14)
Age-standardised prevalence of blindness in Women 50+ years	0.13% (0.10–0.15)	0.01% (0.01–0.01)	0.01% (0.01–0.01)	0.10% (0.08–0.12)	0.09% (0.07–0.12)	0.34% (0.27–0.42)	0.16% (0.12–0.19)	0.11% (0.09–0.14)
Percentage of all blindness	8.60% (7.22–9.99)	2.07% (1.64–2.54)	2.66% (2.11–3.24)	5.96% (4.92–7.04)	6.15% (5.03–7.40)	12.71% (10.58–14.82)	9.34% (7.67–10.94)	5.00% (4.17–5.96)
Number of people with MSVI (thousands)	157,000 (140,000–176,000)	9660 (8560–10,900)	17,100 (15,200–18,900)	14,700 (13,000–16,300)	12,800 (11,400–14,400)	53,900 (47,800–60,900)	39,700 (35,400–44,600)	9620 (8480–10,900)
Number of Men with MSVI (thousands)	73,300 (65,400–81,900)	3830 (3380–4310)	8240 (7300–9150)	6550 (5820–7300)	6380 (5660–7120)	25,600 (22,700–28,900)	18,200 (16,200–20,400)	4520 (3970–5120)
Number of Women with MSVI (thousands)	84,100 (74,900–93,900)	5830 (5180–6600)	8850 (7900–9810)	8140 (7180–9070)	6460 (5740–7240)	28,200 (25,000–31,900)	21,500 (19,200–24,200)	5100 (4500–5760)

Table 1. continued

	GLOBAL	Central Europe, Eastern Europe, and Central Asia	High income	Latin America and Caribbean	North Africa and Middle East	South Asia	Southeast Asia, East Asia, and Oceania	Sub-Saharan Africa
Number of people with MSVI aged 50+ years (thousands)	86,100 (74,200–101,000)	6340 (5400–7480)	8940 (7680–10,400)	5780 (4950–6780)	4680 (3960–5550)	32,150 (27,500–37,900)	25,050 (21,500–29,300)	3210 (2730–3800)
Number of Men with MSVI aged 50+ years (thousands)	39,000 (33,600–45,810)	2270 (1920–2710)	3720 (3200–4310)	2610 (2240–3070)	2280 (1900–2690)	15,600 (13,300–18,400)	11,100 (9550–13,100)	1480 (1260–1750)
Number of Women with MSVI aged 50+ years (thousands)	47,100 (40,600–55,200)	4070 (3470–4780)	5220 (4490–6010)	3170 (2720–3710)	2400 (2030–2840)	16,600 (14,200–19,500)	13,900 (12,000–16,200)	1730 (1470–2050)
Age-standardised prevalence of MSVI	1.91% (1.71–2.13)	1.85% (1.65–2.06)	1.37% (1.21–1.53)	2.39% (2.12–2.65)	2.24% (2.00–2.50)	3.37% (2.99–3.81)	1.60% (1.43–1.78)	1.24% (1.10–1.38)
Age-standardised prevalence of MSVI: Men	1.83% (1.63–2.04)	1.69% (1.50–1.88)	1.41% (1.25–1.60)	2.22% (1.97–2.46)	2.17% (1.93–2.42)	3.25% (2.89–3.65)	1.49% (1.33–1.66)	1.21% (1.08–1.35)
Age-standardised prevalence of MSVI: Women	2.00% (1.78–2.23)	1.98% (1.76–2.22)	1.31% (1.16–1.47)	2.56% (2.27–2.86)	2.32% (2.07–2.59)	3.51% (3.11–3.97)	1.70% (1.52–1.90)	1.27% (1.12–1.42)
Age-standardised prevalence of MSVI 50+ years	4.58% (3.96–5.37)	4.51% (3.85–5.31)	1.94% (1.67–2.25)	4.28% (3.68–5.00)	4.73% (4.02–5.54)	10.28% (8.82–12.06)	3.94% (3.39–4.56)	3.16% (2.73–3.70)
Age-standardised prevalence of MSVI in Men 50+ years	4.41% (3.80–5.16)	3.97% (3.41–4.70)	1.80% (1.55–2.10)	4.21% (3.62–4.92)	4.57% (3.88–5.36)	10.19% (8.74–11.89)	3.66% (3.16–4.26)	3.13% (2.70–3.65)
Age-standardised prevalence of MSVI in Women 50+ years	4.75% (4.09–5.56)	4.89% (4.18–5.76)	2.05% (1.76–2.38)	4.35% (3.74–5.09)	4.88% (4.14–5.72)	10.40% (8.93–12.18)	4.19% (3.62–4.87)	3.19% (2.74–3.74)
Percentage of all MSVI	53.39% (47.56–59.51)	53.69% (47.61–60.63)	55.00% (49.02–60.95)	60.00% (53.21–66.69)	58.76% (52.21–65.72)	55.99% (49.64–63.32)	47.84% (42.61–53.69)	47.06% (41.49–53.29)

Data are presented for the whole population (bold), by sex breakdown and for those 50+ years. Figures in parentheses reflect 95% uncertainty intervals. Count data are presented to three significant figures, and percentages to two decimal places.




Fig. 1 Bar charts demonstrating the number of men and women with blindness and MSVI due to URE in 2000 and 2020 by seven World GBD super-regions and globally. **a** indicates numbers for MSVI and **b** blindness. Note that scales (values should be multiplied by 1000) are not the same between charts, but rather serve to highlight the differences across the time period and sex differences within GBD super-regions.

The overall age-standardised prevalence of blindness due to URE in those aged 50+ years was 0.12% (95% UI 0.10–0.15%), and 4.58% for MSVI (95% UI 3.96–5.37%). Figure 1 shows the number of men and women aged 50+ years with blindness and MSVI due to URE in 2020 in the seven World GBD super regions, and includes the global total for overall comparison. Figure 2 presents the crude prevalence of blindness and MSVI due to URE in 2020 across super regions.

Table 2 presents the percentage change in crude prevalence of MSVI and blindness due to URE in men and women aged 50 years and older between 2000 and 2020 for the seven World GBD super regions (see Appendix 1 for all 21 GBD World regions). Over this time period the number of cases of blindness and MSVI increased

by +21.8% and +72.0% respectively, with the greatest increase in the Latin America and Caribbean super-region for both blindness and MSVI. However, the age-standardised prevalence of URE blindness in those 50+ years decreased significantly, by –30.5% (95% UI –30.7 to –30.3) during this time period. The global age-standardised prevalence of MSVI due to URE in those aged 50+ years modestly decreased by –2.4% (95% UI –2.6 to –2.2%) between 2000 and 2020, but with some regional variations. The Latin America and Caribbean super-region demonstrated a slight increase in age-standardised prevalence of MSVI due to URE of +0.8% (95% UI +0.7 to +1.0%), and the High-Income super-region had no change (+0.1%, 95% UI –0.1 to +0.3).




Fig. 2 Crude prevalence of blindness and MSVI due to URE by region and globally by age. **a** Crude prevalence of blindness due to URE in 2020 by seven World GBD super regions by age. **b** Crude prevalence of MSVI due to URE in 2020 by seven World GBD super regions by age. **c** Crude prevalence of Blindness (red) and MSVI (cyan) due to URE in 2020 globally by age, with 95% UI indicated as shading.

By a clear margin, South Asia had the highest regional 50+ years age-standardised URE blindness and MSVI prevalence in 2020 (blind: 0.3%, 95% UI 0.3–0.4; MSVI: 10.3%; 95% UI 8.8–12.1%) (Table 1), but also demonstrated the greatest reductions in age-standardised URE blindness between 2000 and 2020 (–46.3% (95% UI –46.5 to –46.2%)) (Table 2).

Globally, the age-standardized ratio of women to men for URE blindness was 1.05:1.00 in 2020 and 1.03:1.00 in 2000. For MSVI, this ratio was 1.08:1.00 in 2020 and 1.06:1.00 in 2000. Thus, in 2020, women continue to suffer an excess burden, with the age-standardized prevalence of women exceeding that of men by 4.76% for URE blindness and 7.40% for URE MSVI. Men exhibited a greater 20-year reduction in age-standardised prevalence

compared to women for both blindness and MSVI: MSVI –3.0% (95% UI –3.1 to –2.8) in men, –2.0% (95% UI –2.2 to –1.8) in women; blindness –31.6% (95% UI –31.8 to –31.4) in men, –29.9% (95% UI –30.0 to –29.7) in women. Regionally, women have made smaller gains than men in the reduction of age-standardised prevalence of MSVI due to URE, particularly in the super regions of Central Europe, Eastern Europe and Central Asia, North Africa and Middle East, and Latin America and Caribbean. In the High-Income super-region, age-standardised prevalence of blindness has actually increased modestly for woman at +1.0% (95% UI 0.8 to 1.2%) compared to men –0.1% (95% UI –0.3 to 0.0). However, it is notable that in South Asia, there has been a greater reduction in age-standardised prevalence of both

Table 2. Percentage change in crude prevalence, case number and age-standardised prevalence of MSVI and blindness due to URE in adults aged 50 years and older in the 7 Super Regions between 2000 and 2020.

Region	MSVI caused by URE						Blindness caused by URE					
	Percentage change in Crude Prevalence between 2000 and 2020			Percentage Change in Number of Cases between 2000 and 2020			Percentage Change in Age-standardised prevalence between 2000 and 2020			Percentage Change in Number of Cases between 2000 and 2020		
	Men	Women	Both	Men	Women	Both	Men	Women	Both	Men	Women	Both
GLOBAL	-2.2% (-2.4 to -2.0)	-2.3% (-2.5 to -2.1)	-2.3% (-2.5 to -2.1)	+72.5% (72.2 to 72.8)	+71.6% (71.3 to 71.9)	+72.0% (71.7 to 72.3)	-3.0% (-3.1 to -2.8)	-2.0% (-2.2 to -1.8)	-2.4% (-2.6 to -2.2)	+21.7% (21.4 to 22.1)	+21.9% (21.6 to 22.2)	+21.8% (21.5 to 22.2)
Central Europe, Eastern Europe & Central Asia	-1.1% (-1.3 to -0.9)	-2.2% (-2.4 to -2.0)	-2.1% (-2.3 to -1.9)	+28.3% (28.1 to 28.6)	+21.0% (20.7 to 21.2)	+23.5% (23.3 to 23.7)	-2.3% (-2.5 to -2.1)	-2.3% (-2.5 to -2.2)	-2.8% (-2.9 to -2.6)	+8.0% (7.6 to 8.3)	+10.0% (9.7 to 10.4)	+9.2% (8.8 to 9.5)
High Income	+5.3% (5.1 to 5.5)	+3.6% (3.4 to 3.8)	+4.0% (3.8 to 4.2)	+55.0% (54.7 to 55.2)	+44.3% (44.1 to 44.6)	+48.6% (48.3 to 48.8)	-0.1% (-0.3 to 0.0)	+1.0% (0.8 to 1.2)	+0.1% (-0.1 to 0.3)	+40.4% (40.0 to 40.8)	+32.9% (32.5 to 33.2)	+36.2% (35.8 to 36.6)
Latin America and Caribbean	+1.4% (1.2 to 1.6)	+2.3% (2.1 to 2.5)	+1.9% (1.8 to 2.1)	+99.8% (99.4 to 100.2)	+109.4% (109.1 to 109.8)	+105.0% (104.6 to 105.4)	+0.4% (0.2 to 0.5)	+1.2% (1.0 to 1.4)	+0.8% (0.7 to 1.0)	+67.5% (67.1 to 68.0)	+87.3% (86.8 to 87.8)	+78.3% (77.9 to 78.8)
North Africa and Middle East	-11.8% (-12.0 to -11.6)	-9.6% (-9.8 to -9.4)	-10.7% (-10.9 to -10.5)	+83.2% (82.9 to 83.6)	+88.1% (87.8 to 88.5)	+85.7% (85.4 to 86.1)	-9.0% (-9.2 to -8.8)	-8.1% (-8.3 to -7.9)	-8.5% (-8.7 to -8.3)	+51.7% (51.3 to 52.2)	+66.0% (65.5 to 66.4)	+59.0% (58.5 to 59.5)
South Asia	-3.3% (-3.5 to -3.2)	-8.5% (-8.7 to -8.3)	-5.9% (-6.1 to -5.7)	+82.4% (82.1 to 82.8)	+85.0% (84.7 to 85.4)	+83.8% (83.4 to 84.1)	-4.3% (-4.5 to -4.1)	-8.9% (-9.1 to -8.8)	-6.7% (-6.8 to -6.5)	+14.5% (14.2 to 14.8)	+6.7% (6.4 to 7.0)	+10.2% (9.9 to 10.5)
Southeast Asia, East Asia and Oceania	-13.5% (-13.7 to -13.4)	-12.2% (-12.3 to -12.0)	-12.7% (-12.8 to -12.5)	+71.0% (70.7 to 71.3)	+79.2% (78.9 to 79.5)	+75.5% (75.1 to 75.8)	-14.9% (-15.1 to -14.8)	-12.3% (-12.5 to -12.2)	-13.5% (-13.7 to -13.4)	+19.9% (19.6 to 20.2)	+27.0% (26.6 to 27.3)	+23.7% (23.4 to 24.0)
Sub-Saharan Africa	-4.9% (-5.1 to -4.7)	-5.2% (-5.3 to -5.0)	-4.9% (-5.1 to -4.7)	+68.3% (68.0 to 68.6)	+84.0% (83.6 to 84.4)	+76.4% (76.1 to 76.8)	-3.7% (-3.8 to -3.5)	-3.3% (-3.5 to -3.1)	-3.4% (-3.5 to -3.2)	+54.3% (53.8 to 54.7)	+61.5% (61.1 to 62.0)	+58.0% (57.6 to 58.4)
							-12.6% (-12.6 to -12.6)	-16.5% (-16.5 to -16.5)	-14.6% (-14.6 to -14.6)			

Percentage change to 1 decimal place and figures in parentheses reflect 95% uncertainty intervals. Data in bold indicate totals for both sexes.

Table 3. Number and age-standardised prevalence of people with uncorrected presbyopia aged 50+ years (>N6/N8 at 40 cm when best-corrected distance visual acuity was 6/12 or better) in 7 Super Regions in 2020.

	GLOBAL	Central Europe, Eastern Europe, and Central Asia	High income	Latin America and Caribbean	North Africa and Middle East	South Asia	Southeast Asia, East Asia, and Oceania	Sub-Saharan Africa
Total population 2020 (thousands)	7,890,000	417,000	1,090,000	602,000	632,000	1,840,000	2,190,000	1,110,000
Number of people with uncorrected presbyopia (aged 50+ years) (thousands)	419,000 (295,000–562,000)	39,800 (28,300–53,500)	11,400 (7700–15,900)	24,910 (17,600–33,600)	12,200 (8410–16,800)	124,000 (86,600–166,000)	169,000 (118,000–227,000)	37,800 (27,200–49,700)
Number of Men with uncorrected presbyopia (thousands)	186,000 (130,000–251,000)	14,500 (10,200–19,600)	5020 (3400–6970)	11,200 (7820–15,100)	5800 (3900–8020)	57,900 (40,500–78,300)	75,000 (52,000 to 102,000)	17,000 (12,200–22,400)
Number of Women with uncorrected presbyopia (thousands)	233,000 (164,000–311,000)	25,300 (18,200–33,900)	6350 (4300–8900)	13,700 (9700–18,500)	6440 (4470–8770)	66,300 (46,310 to 88,100)	93,700 (66,000–125,000)	20,700 (15,000 to 27,200)
Age-standardised prevalence of uncorrected presbyopia	22.33% (15.81–29.91)	27.81% (19.89–37.41)	2.37% (1.59–3.31)	18.85% (13.33–25.38)	13.18% (9.23–17.89)	38.89% (28.30–53.17)	26.63% (18.81–35.78)	37.54% (27.33–49.08)
Age-standardised prevalence of uncorrected presbyopia: Men	21.11% (14.92–28.29)	25.89% (18.51–34.58)	2.35% (1.57–3.28)	18.66% (13.19–25.16)	12.60% (8.72–17.27)	37.78% (26.71–50.35)	24.71% (17.51–33.29)	36.30% (26.31–47.28)
Age-standardised prevalence of uncorrected presbyopia: Women	23.43% (16.52–31.36)	29.10% (20.93–39.08)	2.38% (1.60–3.33)	19.01% (13.44–25.69)	13.74% (9.66–18.68)	41.93% (29.63–55.68)	28.36% (19.94–38.00)	38.62% (28.12–50.22)

Data in parentheses are 95% uncertainty intervals. Count data are presented to three significant figures, and percentages to two decimal places. Data in bold indicate totals for both sexes.

blindness and MSVI for women compared to men (percentage reduction blindness; women -50.0% (95% UI -50.2 to -49.9), men -42.1% (95% UI -42.2 to -41.9); percentage reduction MSVI; women -8.9% (95% UI -9.1 to -8.8), men -4.3% (95% UI -4.5 to -4.1)), although the burden remains substantial.

Table 3 presents the number of people, men and women with near VI from uncorrected presbyopia in the seven super regions. In 2020, an estimated 419 million (95% UI 295–562 million) people aged 50+ had near VI from uncorrected presbyopia globally, with an age-standardised prevalence of 22.3% (95% UI 15.8–29.9%). Approximately 70% of global near VI from presbyopia occurred in two super regions: South Asia and Southeast Asia, East Asia and Oceania (293 million).

Table 4 presents the percentage change in crude prevalence of near VI due to uncorrected presbyopia in men and women aged 50 years and older between 2000 and 2020. Over this time period, the number of cases of near VI due to presbyopia increased substantially ($+75.3\%$ (95% UI $+74.6$ to $+76.0$)), while the crude prevalence demonstrated a modest reduction for men (-1.8% (95% UI -2.2 to -1.4%)), but an increase of $+0.8\%$ (95% UI 0.4 – 1.2%) for women. Figure 3 further illustrates these sex differences across super regions, demonstrating significant increases in the number of cases in the 20-year period, with a disproportionate increase for women. The number of cases of near VI due to presbyopia increased in all super regions, ranging from 25.5% (95% UI $+25.0$ to $+25.9\%$) in Central Europe, Eastern Europe, and Central Asia to 101% (95% UI $+100.2$ to $+101.7\%$) in Latin America and Caribbean super-region. However, the percentage change in crude prevalence decreased in all super regions over the 20-year period except for the High-Income super-region which had a $+4.3\%$ (95% UI $+3.9$ to $+4.7$) increase.

DISCUSSION

This study provides up-to-date global and regional, sex-specific and age-specific estimates and temporal trends for vision impairment due to URE, both for distance and near vision impairment. Our study reveals that URE remains a leading cause of MSVI, affecting 157 million individuals worldwide in 2020, and MSVI due to URE accounts for 57% of all MSVI globally. Notably, although there is some variation across the super regions, the percentage of MSVI due to URE remains above 47% in all areas, underscoring the persistent and substantial global burden of avoidable vision loss caused by URE.

In the 20-year period up to 2020, VISION 2020: the Right to Sight initiative sought to prevent avoidable sight loss, and the subsequent Global Action Plan adopted by the WHA in 2013 set a target for a 25% reduction in the prevalence of avoidable vision impairment by 2019 from the baseline of 2010. While progress in reducing the global burden has been made, this target was not achieved [29], highlighting the need for continued focus and effort to eliminate avoidable sight loss.

Encouragingly, the age-standardised prevalence of blindness due to URE in those aged 50+ years has decreased substantially from 2000 to 2020, potentially reflecting the targeted efforts countries have adopted to tackle severe sight loss. This may in part be explained by the increased use of intra-ocular lenses in cataract surgery over the last 20–30 years, leading to a reduction in blindness due to aphakia [38]. In contrast, the age-standardised prevalence of MSVI due to URE in those aged 50+ years only decreased modestly between 2000 and 2020.

The reductions we observed in age-standardised prevalence are counterbalanced by a striking increase in the unadjusted burden of blindness and MSVI due to URE, meaning that the total number of affected persons in the world has risen. This is driven by two key factors: continued global population growth, which is estimated to reach 10.4 billion in 2100, and an ageing population

[39]. In common with the majority of vision-impairing ocular diseases, the likelihood of MSVI and blindness due to URE rapidly increases with age, as shown in Fig. 2. UN projections report that between 2020 and 2050 the global population of those aged 65+ years is expected to double from 703 million to 1.5 billion, and that by 2050, one in six people in the world will be aged ≥ 65 years [40].

The super-region of South Asia, comprising countries including India and Pakistan, had the greatest burdens of blindness and MSVI, with a disproportionately high prevalence of older age groups. While globally there was a reduction in age-standardised prevalence of MSVI due to URE, the super-region of Latin America and Caribbean actually demonstrated an increase of $+0.8\%$ (95% UI 0.4 – 1.3). These regional differences in the prevalence of vision loss are likely due to variations in availability of affordable refractive services, particularly in rural locations, and in social conditions. This is evidenced by a recent study investigating the eREC across regions, which demonstrated substantial differences in eREC between super regions in 2021, with 79.1% coverage in the High-Income super-region (95% CI 72.4–85.0), compared to 6.7% in Sub-Saharan Africa (95% CI 3.1–9.0) and 9.0% in South Asia (95% CI 6.5–12.0%) [41].

New eyecare service development has not kept pace with the increasing population demands in any region of the world, and continued population ageing will further increase existing burdens. Alleviating this shortfall will require a combination of capacity-building of trained eyecare personnel, expansion of community-based screening services for diagnosis of refractive errors, development of infrastructure for spectacle provision, outreach efforts to drive demand, and novel technical approaches to allow more services to be delivered by available, less fully-trained cadres. The WHO World Report on Vision, 2019 [17] sets out four key areas to increase access to eyecare services: (i) Increase of the availability of services through training and improved infrastructure; (ii) Increase the accessibility of services to those who need them; (iii) Increase the affordability of services, and (iv) Increase of the acceptability of refractive services, through awareness raising.

While the burden of vision impairment increases with age, focusing only on the population aged 50 years and above provides an incomplete view of vision impairment due to URE, which also frequently affects younger persons. While we report that those aged 50+ years with MSVI total 86 million in 2020, this only accounts for 55% of all MSVI (167 million). For younger people, the burden of URE is likely driven by the concerning global increase in myopia [42], with recent evidence showing these trends are not only confined to Asian populations [43]. However, there remains a paucity of data on vision impairment due to URE in children and younger adults, which needs to be redressed.

A disproportionate number of women continue to be affected by vision impairment due to URE. This is observed globally and across the majority of super regions. Interestingly for presbyopia, while the global crude prevalence decreased for men by -1.8% (-2.2 to -1.4%) from 2000 to 2020, there was an increase for women of $+0.8\%$ ($+0.4$ to $+1.2\%$). It is important to emphasise that these differences persist after age adjustment, and are not simply an artefact of women living longer. This unfair burden among women is likely driven by cultural and social inequities, with less financial autonomy, male prioritisation, and child- and home-care responsibilities [44]. This persistent gap must be addressed through targeted strategies to increase their access to refractive care.

The burden of near visual impairment due to uncorrected presbyopia is another critical area of concern highlighted by our study, with nearly 420 million people aged 50+ years affected by uncorrected presbyopia. There are huge disparities in the age-standardised prevalence of uncorrected presbyopia across super

Table 4. Percentage change in crude prevalence and case number of uncorrected presbyopia in adults aged 50 years and older in the 7 Super Regions between 2000 and 2020.

Near VI caused by uncorrected presbyopia						
Region	Percentage Change in Crude Prevalence between 2000 and 2020			Percentage Change in Number of Cases between 2000 and 2020		
	Men	Women	Both	Men	Women	Both
GLOBAL	−1.8% (−2.2 to −1.4)	+0.8% (+0.4 to +1.2)	−0.4% (−0.8 to 0.0)	+73.2% (+72.5 to +73.8)	+77.1% (+76.4 to +77.7)	+75.3% (+74.6 to +76.0)
Central Europe, Eastern Europe & Central Asia	0.0% (−0.4 to +0.4)	−0.5% (−0.9 to −0.1)	−0.6% (−0.9 to −0.2)	+29.8% (+29.3 to +30.3)	+23.1% (+22.7 to +23.6)	+25.5% (+25.0 to +25.9)
High Income	+8.1% (+7.6 to +8.5)	+1.9% (+1.5 to +2.3)	+4.3% (+3.9 to +4.7)	+59.0% (+58.3 to +59.7)	+41.9% (+41.3 to +42.5)	+49.0% (+48.4 to +49.6)
Latin America and Caribbean	−1.2% (−1.6 to −0.8)	+0.8% (+0.4 to +1.2)	−0.1% (−0.4 to 0.3)	+94.8% (+94.0 to +95.5)	+106.3% (+105.5 to +107.1)	+101.0% (+100.2 to +101.7)
North Africa and Middle East	−11.2% (−11.6 to −10.9)	−10.1% (−10.5 to −9.8)	−10.7% (−11.0 to −10.3)	+84.5% (+83.7 to +85.2)	+87.0% (+86.2 to +87.7)	+85.8% (+85.0 to +86.6)
South Asia	−8.0% (−8.3 to −7.6)	−7.0% (−7.3 to −6.6)	−7.3% (−7.6 to −6.9)	+73.7% (+73.1 to +74.4)	+88.1% (+87.4 to +88.8)	+81.1% (+80.4 to +81.8)
Southeast Asia, East Asia and Oceania	−6.5% (−6.9 to −6.2)	−6.6% (−6.9 to −6.2)	−6.4% (−6.8 to −6.1)	+84.8% (+84.1 to +85.6)	+90.6% (+89.8 to +91.3)	+88.0% (+87.3 to +88.7)
Sub-Saharan Africa	−8.7% (−9.0 to −8.4)	−9.4% (−9.7 to −9.0)	−8.9% (−9.2 to −8.5)	+61.5% (+61.0 to +62.1)	+75.9% (+75.2 to +76.5)	+69.1% (+68.5 to +69.7)

Percentage change to 1 decimal place and figures in parentheses reflect 95% uncertainty intervals.

regions, with for example, only a 2.4% prevalence in the High-Income super-region compared with 38.9% in South Asia. This finding is supported by a systematic review reporting the greatest burden of presbyopia in rural areas in low-resource countries [45]. Looking at temporal data, some super regions demonstrated a reduction in crude prevalence but in all areas the number of cases increased significantly, likely due to the ageing population globally and also improvements in data availability in the last 20 years. It was not possible to generate age-standardised estimates due to sparsity of data. The combination of high, rapidly rising burden and the paucity of data underscores the need for more attention to presbyopia among both researchers and health service planners.

The large burden of uncorrected presbyopia may in part reflect a view that correction for near VI is somehow less important than for distance VI, but studies have shown that vision impairment from URE affects the quality of life to a similar degree whether at distance or near VI [14]. Furthermore, a recent study [46] reported on the considerable productivity loss from un- and under-corrected presbyopia in LICs and LMICs. Using GBD data, the authors estimated 238 million people of working age (15–65 years) in LMICs had uncorrected presbyopia, and estimated the resulting direct productivity loss at \$54 billion dollars, using productivity-adjusted-life-years. The potential for presbyopic correction to improve real-world work productivity is underscored by recent trials [2].

The strengths of this updated review and data analysis up to 2020 include the addition of new data sources, particularly more RAAB surveys, which enable improvements in disaggregation by cause and a wider coverage of geographical regions in our analysis. This is also the first time we combine reports on the impact of distance and near visual impairment due to URE and presbyopia. However, there remain several LICs and LMICs in regions such as central sub-Saharan Africa, Central Asia, and central and eastern Europe, with scant population-based data where estimates rely on extrapolation from other regions. While our modelling has controlled for a range of confounding factors, it is possible that blindness and MSVI due to URE are under-reported. Furthermore, due to data sparsity, we did not include mild visual impairment in this dataset but used a definition of <6/18 for MSVI, so again these data underreport the potential burden of distance vision impairment compared to other studies. Finally, it is possible that the trajectory of the prevalence of vision impairment due to URE might be altered owing to the COVID-19 global pandemic, with reports emerging of an increase in the prevalence of myopia attributed to changes in lifestyle during the pandemic [47]. Future directions for research and policy should be develop population screening services, accurate reporting mechanisms and registries to effectively measure the burden of avoidable vision impairment due to URE, to strengthen data from younger populations, and focus efforts on developing refractive services in LICs and LMICs to fill the data gaps to achieve greater geographical coverage.

CONCLUSIONS

Data from the last 20 years show that the absolute number of people with URE is rising due to population growth and ageing. URE remains a leading global cause of MSVI among persons aged 50+ years, affecting 86 million individuals and accounting for 53.4% of the total figure. This, coupled with the huge burden of near vision impairment due to uncorrected presbyopia, highlights the urgent need for novel and fresh approaches to refractive service delivery. While progress has been made in the last two decades, a reduction in the burden of vision impairment from URE can be realised by adding refractive services to universal health coverage and otherwise improving availability of, and access to, spectacle provision. Though the




Fig. 3 Comparison of the number of men and women with near vision impairment due to uncorrected presbyopia in 2000 and 2020 by seven World GBD super regions, with Global total bottom right panel. Note scales (values should be multiplied by 1000) are not the same between charts, but rather serve to highlight the differences across the time period and sex differences within GBD super regions.

need is greater in some global regions, URE has not been fully addressed anywhere, and the resulting productivity losses and reduction in quality of life should not be overlooked for any country. Over this decade, the target set by the 73rd WHA member states in 2021, a 40% increase in eREC by 2030, will provide critical leverage to accelerate our efforts to tackle avoidable blindness due to URE.

URE remains the leading cause of MSVI, though spectacle provision is the simplest and least invasive treatment available for any ocular condition. This is a source of frustration after decades of work on VISION 2020, but it underscores the opportunity to accelerate progress towards what is arguably the most attainable goal in vision care, that of eliminating URE.

SUMMARY

What was known before

- Uncorrected refractive error (URE) is the leading cause of vision impairment globally among both adults and children, and contributes to reduced educational and economic opportunities, decreased quality of life and an increased burden of mortality
- Visual impairment is a significant global health concern, and the 'World Report on Vision' by the World Health Organisation in 2019 called for the routine measurement of refractive error services coverage as a means to address the UN Sustainable Development Goal 3.8 of universal health coverage
- Uncorrected refractive error (URE) is readily treated with spectacles, making it one of the most cost-effective healthcare interventions, both for distance visual impairment and near visual impairment due to presbyopia
- The need for new population data on vision impairment is vital to monitor and measure success against global targets to increase the coverage of refractive error services by 40% by 2030

What this study adds

- This study provides up-to-date global and regional, sex-specific and age-specific estimates and temporal trends for vision impairment due to uncorrected refractive error, both for distance and near vision impairment.
- We examined age-adjusted and sex-adjusted differences in the contribution of uncorrected refractive error to vision impairment, with a focus on older age groups
- We incorporated studies from an updated systematic review for a total of 243 sources from 73 countries
- Our study reveals that over the last 20 years, the absolute number of people with URE has risen due to population growth and ageing, with a continued disproportionate burden by region and sex
- Uncorrected refractive error (URE) remains a leading cause of MSVI, affecting 157 million individuals worldwide in 2020, and MSVI due to URE accounts for 57% of all MSVI globally
- Furthermore, an estimated 419 million people aged 50+ had near VI from uncorrected presbyopia globally in 2020
- These data underscore the persistent and substantial global burden of avoidable vision loss caused by uncorrected refractive error, highlighting the urgent need for novel and fresh approaches to refractive service delivery.

DATA AVAILABILITY

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the coordinator of the Vision Loss Expert Group (Professor Rupert Bourne; rb@rupertbourne.co.uk) upon reasonable request. Data are located in controlled access data storage at Anglia Ruskin University.

REFERENCES

1. Ma X, Zhou Z, Yi H, Pang X, Shi Y, Chen Q, et al. Effect of providing free glasses on children's educational outcomes in China: cluster randomized controlled trial. *BMJ*. 2014;349:23.

2. Reddy PA, Congdon N, MacKenzie G, Gogate P, Wen Q, Jan C, et al. Effect of providing near glasses on productivity among rural Indian tea workers with presbyopia (PROSPER): a randomised trial. *Lancet Glob Health*. 2018;6:e1019–e1027.
3. Slavin RE, Collins ME, Repka MX, Friedman DS, Mudie LI, Owoeye JO, et al. In plain sight: reading outcomes of providing eyeglasses to disadvantaged children. *J Educ Stud Placed Risk*. 2018;23:250–8.
4. Naidoo KS, Fricke TR, Frick KD, Jong M, Naduvilath TJ, Resnikoff S, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modelling. *Ophthalmology*. 2019;126:338–46.
5. Nie JC, Pang XP, Wang L, Rozelle S, Sylvia S. Seeing is believing: experimental evidence on the impact of eyeglasses on academic performance, aspirations, and dropout among junior high school students in rural China. *Econ Dev Cult Change*. 2020;68:335–55.
6. Marques AP, Ramke J, Cairns J, Butt T, Zhang JH, Muirhead D, et al. Global economic productivity losses from vision impairment and blindness. *E Clin. Med*. 2021;35:26.
7. Ramrattan RS, Wolfs RC, Panda-Jonas S, Jonas JB, Bakker D, Pols HA, et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. *Arch Ophthalmol*. 2001;119:1788–94.
8. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. *Br J Ophthalmol*. 2001;85:322–6.
9. Lee DJ, Gómez-Marín O, Lam BL, Zheng DD. Visual acuity impairment and mortality in US adults. *Arch Ophthalmol*. 2002;120:1544–50.
10. Ehrlich JR, Ramke J, Macleod D, Burn H, Lee CN, Zhang JH, et al. Association between vision impairment and mortality: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9:e418–e430.
11. Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, et al. The Lancet Global Health Commission on Global Eye Health: Vision Beyond 2020. *Lancet Glob Health*. 2021;9:e489–e551.
12. Baltussen R, Naus J, Limburg H. Cost-effectiveness of screening and correcting refractive errors in school children in Africa, Asia, America and Europe. *Health Policy*. 2009;89:201–15.
13. Frick KD, Riva-Clement L, Shankar MB. Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness. *Ophthalmic Epidemiol*. 2009;16:378–87.
14. Fricke TR, Holden BA, Wilson DA, Schlenther G, Naidoo KS, Resnikoff S, et al. Global cost of correcting vision impairment from uncorrected refractive error. *Bull World Health Organ*. 2012;90:728–38.
15. Tahhan N, Papas E, Fricke TR, Frick KD, Holden BA. Utility and uncorrected refractive error. *Ophthalmology*. 2013;120:1736–44.
16. WHO. World Health Organization; Geneva: 2013. Universal eye health: a global action plan 2014–2019. <https://www.who.int/publications/i/item/universal-eye-health-a-global-action-plan-2014-2019> Accessed 13 Feb 2023.
17. World Health Organisation. World report on vision. Geneva; 2019. <https://www.who.int/publications/i/item/9789241516570> Accessed 13 Feb 2023.
18. United Nations. Sustainable Development Goals. 2015. <https://sdgs.un.org/goals> Accessed 14 May 2023.
19. Hashemi H, Fotouhi A, Yekta A, Pakzad R, Ostadimoghaddam H, Khabazkhoob M. Global and regional estimates of prevalence of refractive errors: Systematic review and meta-analysis. *J Curr Ophthalmol*. 2017;30:3–22.
20. Sun HP, Li A, Xu Y, Pan CW. Secular trends of reduced visual acuity from 1985 to 2010 and disease burden projection for 2020 and 2030 among primary and secondary school students in China. *JAMA Ophthalmol*. 2015;133:262–8.
21. Lee JH, Jee D, Kwon JW, Lee WK. Prevalence and risk factors for myopia in a rural Korean population. *Invest Ophthalmol Vis Sci*. 2013;54:5466–71.
22. He MG, Zeng JW, Liu YZ, Xu JJ, Pokharel GP, Ellwein LB. Refractive error and visual impairment in urban children in southern China. *Invest Ophthalmol Vis Sci*. 2004;45:793–9.
23. Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, et al. Interventions to slow progression of myopia in children. *Cochrane Database Syst Rev*. 2020;1:13.
24. Mountjoy E, Davies NM, Plotnikov D, Smith GD, Rodriguez S, Williams CE, et al. Education and myopia: assessing the direction of causality by Mendelian randomisation. *BMJ*. 2018;361:6.
25. Marmamula S, Narsaiah S, Shekhar K, Khanna RC, Rao GN. Visual Impairment in the South Indian State of Andhra Pradesh: Andhra Pradesh – Rapid Assessment of Visual Impairment (AP-RAVI) Project. *PLoS ONE*. 2013;8:e70120.
26. Ahmed M, Shefali MK, Husain L, Khondaker M, Alauddin M, Hossain MA, et al. Vision impairment and productivity among female garment workers in Bangladesh: a cohort study. *Asia Pac J Ophthalmol*. 2022;11:79–84.
27. Bourne RRA, Flaxman SR, Braithwaite T. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5:e888–e897.
28. Flaxman SR, Bourne RRA, Resnikoff S. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5:e1221–e1234.
29. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021;9:e144–e160.
30. Ramke J, Evans JR, Habtamu E, Mwangi N, Silva JC, Swenor BK, et al. Grand Challenges in Global Eye Health study group. Grand Challenges in global eye health: a global prioritisation process using Delphi method. *Lancet Healthy Longev*. 2022;3:e31–e41.
31. Bourne RRA, Steinmetz, Flaxman J, Briant SR, Taylor HRB PS, Resnikoff S, et al. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. *Lancet Global Health*. 2021;9:e130–e143.
32. International Classification of Diseases 11th edition <https://icd.who.int/browse11/l-m/en#/http%253a%252f%252fcd.who.int%252fcd%252fentfity%252f1103667651> Accessed 14 May 2023.
33. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. GBD 2019 Diseases, Injuries, and Impairments Collaborators. Global burden of 359 diseases, injuries, and impairments, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–22.
34. James SL, Abate D, Hassan AK, Abay SM, Abbafati C, et al. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392:1789–858.
35. Vollset SE, Goren E, Yuan C-W, Cao J, Smith A, Hsiao T, et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. *Lancet*. 2020;396:1285–306.
36. Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *Lancet*. 2016;388:e19–23.
37. IAPB Vision Atlas, List of Seven Super Regions <https://www.iapb.org/learn/vision-atlas/about/definitions-and-regions/> Accessed 13 June 2022.
38. Han X, Zhang J, Liu Z, Tan X, Jin G, He M, et al. Real-world visual outcomes of cataract surgery based on population-based studies: a systematic review. *Br J Ophthalmol*. (2022). <https://doi.org/10.1136/bjophthalmol-2021-320997>.
39. United Nations (UN) Department of Economic and Social Affairs World Population Prospects 2022. www.un.org/development/desa/pd/files/wpp2022_summary_of_results.pdf Accessed 13 Feb 2023.
40. UN World Population Ageing Report 2019 <https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf> Accessed 13 Feb 2023.
41. Bourne RRA, Cicinelli MV, Sedighi T, Tappay IH, McCormick I, Jonas JB, et al. Effective refractive error coverage in adults aged 50 years and older: estimates from population-based surveys in 61 countries. *Lancet Glob Health*. 2022;10:e1754–e1763.
42. Morgan IG, French AN, Ashby RS, Guo X, Ding X, He M, et al. The epidemics of myopia: aetiology and prevention. *Prog Retin Eye Res*. 2018;62:134–49.
43. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmology*. 2016;123:1036–42.
44. Courtright P, Lewallen S. Why are we addressing gender issues in vision loss? *Community Eye Health*. 2009;22:17–9.
45. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. *Ophthalmology*. 2018;125:1492–9.
46. Ma Q, Chen M, Li D, Zhou R, Du Y, Yin S, et al. Potential productivity loss from uncorrected and under-corrected presbyopia in low- and middle-income countries: a life table modelling study. *Front Public Health*. 2022;10:983423.
47. Li M, Xu L, Tan CS, Lanca C, Foo LL, Sabanayagam C, et al. Systematic review and meta-analysis on the impact of COVID-19 pandemic-related lifestyle on myopia. *Asia Pac J Ophthalmol*. 2022;11:470–80.

AUTHOR CONTRIBUTIONS

Please see Appendix 2 for more detailed information about individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or

coding figures and tables; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process.

FUNDING

This study was funded by Brien Holden Vision Institute, Foundation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation (LCIF), Sightsavers International, and University of Heidelberg.

COMPETING INTERESTS

GBD 2019 Blindness and Vision Impairment Collaborators: N J Adderley reports grants or contracts paid to their institution from the National Institute for Health and Care Research, UKRI Medical Research Council, Clinical Research Network West Midlands, and Action Against AMD. S Afzal reports support for the present manuscript from King Edward Medical University, Department of Community Medicine which provided study materials, research article, supporting staff and office for working on the manuscript; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from King Edward Medical University; participation on a Data Safety Monitoring Board or Advisory Board with the National Bioethics Committee Pakistan, King Edward Medical University Institutional Ethical Review Board and Ethical Review Committee in Board of Faculty, and Ethical Review Board Fatima Jinnah Medical University and Sir Ganga Ram Hospital; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, Pakistan Association of Medical Editors, Fellow of Faculty of Public Health Royal Colleges UK (FFPH), Society of Prevention, Advocacy And Research, King Edward Medical University. (SPARK), Member Pakistan Society of Infectious Diseases, Member Pakistan Society of Internal Medicine, Member Pakistan Society of Community Medicine and Public Health; other financial or non-financial interests in the Higher Education Commission of Pakistan as a member Research and Publications Committee, and Pakistan Medical and Dental Council as a member Journal Research Evaluation Committee; all outside the submitted work. O C Baltatu reports support for the present manuscript from National Council for Scientific and Technological Development (CNPq, 304224/2022-7), and Anima Institute - AI research professor fellowship; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the Health and Biotechnology Board at São José dos Campos Technology Park, and Afya – UNINOVAFAP as Academic Ambassador; all outside the submitted work. T W Bärnighausen reports grants from the European Union (Horizon 2020 and EIT Health), German Research Foundation (DFG), US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius - Foundation, Wellcome Trust, Bill & Melinda Gates Foundation, KfW, UNAIDS, and WHO; consulting fees from KfW on the OSCAR initiative in Vietnam; participation on a Data Safety Monitoring Board or Advisory Board with the NIH-funded study “Healthy Options”, Chair, Data Safety and Monitoring Board (DSMB), German National Committee on the “Future of Public Health Research and Education”, Chair of the scientific advisory board to the EDCTP Evaluation, Member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS, US National Academies of Sciences, Engineering, and Medicine’s Committee for the “Evaluation of Human Resources for Health in the Republic of Rwanda under the President’s Emergency Plan for AIDS Relief”, and University of Pennsylvania Population Aging Research Center External Advisory Board Member; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the Global Health Hub Germany; all outside the submitted work. S Bhaskar reports grants or contracts from the Japan Society for the Promotion of Science (JSPS), JSPS International Fellowship, Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Australian Academy of Science, Grant-in-Aid for Scientific Research (KAKENHI); leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Rotary District 9675 as the District Chair of Diversity, Equity, and Inclusion; the Global Health & Migration Hub Community and the Global Health Hub Germany (Berlin, Germany) as the Chair and Manager; PLOS One, BMC Neurology, Frontiers In Neurology, Frontiers in Stroke, Frontiers in Public Health and BMC Medical Research Methodology as an Editorial Board Member, outside the submitted work. R Bourne reports support for the present manuscript to their institution from the World Health Organization (WHO), Brien Holden Vision Institute, Foundation Thea, Fred Hollows Foundation, Lions Clubs International Foundation; and grants or contracts to their institution from Sightsavers International and the University of Heidelberg. M Cenderadewi reports grants or contracts from James Cook University (International Research Training Program Scholarship for doctoral study), and support for attending meetings and travel from James Cook University; all outside the submitted work. N Congwon

reports grants or contracts paid to their institute from the Wellcome Trust Investigator Award. X Dai and J D Steinmetz report support for the present manuscript from the Bill and Melinda Gates Foundation as payments to IHME for the GBD Study. A Dastridiou reports support for attending meetings and/or travel from THEA and ABBVIE; outside the submitted work. T Fricke reports a grant from the International Myopia Institute, and contracts from the Brien Holden Vision Institute and the Victorian Lions Foundation, all paid to the Australian College of Optometry; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the University of Melbourne and UNSW Sydney; support from attending meetings and travel from the International Myopia Conference as a presenter, and UNSW Sydney as a PhD Candidate; all outside the submitted work. J M Furtado reports consulting fees from SightFirst and Pan American Health Organization; outside the submitted work. I M Illic reports support for the present manuscript from Ministry of Education, Science and Technological development, Republic of Serbia (project No 175042, 2011-2023). S M S Islam reports grants from NHMRC and the Heart Foundation, outside the submitted work. F Ghassemi reports support for the present manuscript from medical writing. V K Gupta reports grants or contracts from National Health and Medical Research Council (NHMRC), Australia, as payments to their institutions; all outside the submitted work. J H Kempen reports support for the present manuscript from Sight for Souls and Mass Eye and Ear Global Surgery Program. K Krishan reports non-financial support from UGC Centre of Advanced Study, CAS II, Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. V C Lingsingh reports consulting fees from HelpMeSee; and support for attending meetings and travel from HelpMeSee; all outside the submitted work. J L Leasher reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as a member of the National Eye Institute National Eye Health Education Program planning committee; outside the submitted work. M Lee reports support for the present manuscript from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2021R111A4A01057428) and Bio-convergence Technology Education Program through the Korea Institute for Advancement Technology (KIAT) funded by the Ministry of Trade, Industry and Energy (No. P0017805). K S Naidoo reports other financial support from OneSight EssilorLuxottica Foundation as an employee; outside the submitted work. M Saylan reports support for attending meetings and/or travel from Janssen Pharmaceuticals; outside the submitted work. J A Singh reports consulting fees from AstraZeneca, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point communications, and the National Institutes of Health and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the speaker’s bureau of Simply Speaking; support for attending meetings from OMERACT as a member of the steering committee; participation on an Advisory Committee with the FDA Arthritis Advisory Committee; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as a past steering committee member of the OMERACT, an international organization that develops measures for clinical trials and receives arms length funding from 12 pharmaceutical companies, Co-Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzytecs Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlotte’s Web Holdings, Inc, as well as previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals; outside the submitted work. Y S Samodra reports grants or contracts from Taipei Medical University; and other financial or non-financial interests as the co-founder of Benang Merah Research Center, outside the submitted work. N Tahhan reports support for attending meetings and travel from the Brien Holden Foundation to the ISER Conference; outside the submitted work. Y Tan reports support for the present manuscript from the Department of Ophthalmology and the Hospital Central South University and Postdoctoral Station of Clinical Medicine, The Third Xiangya Hospital of Central South University. J H V Ticoalu reports other financial or non-financial support as a co-founder of Benang Merah Research Center; outside the submitted work.

Vision Loss Expert Group of the Global Burden of Disease Study: A Bron reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Théa. N Congdon reports grants or contracts from any entity from Wellcome Trust and MRC; consulting fees from Belkin Vision; and support for attending meetings and/or travel from Singapore National Eye Center. M A Del Monte reports support for attending meetings and/or travel from the University of Michigan, and leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as past president of Costenbader Society. T Fricke reports grants or contracts from any entity from Brien Holden Vision Institute,

Victorian Lions Foundation, International Myopia Institute, and Australian government; and support for attending meetings and/or travel from International Myopia Institute. D Friedman reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from Orbis International as member of board of governors. J M Furtado reports consulting fees from Pan American Health Organization and from Lions Club International Foundation. G Gazzard reports consulting fees from Alcon Laboratories, Inc; Allergan, Inc; BELKIN Vision Ltd; Carl Zeiss Meditec; Elios; Genentech/Roche; Reichert; Théa and ViaLase; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alcon Laboratories, Inc; BELKIN Vision Ltd; Carl Zeiss Meditec; Elios and Ellex; participation on a Data Safety Monitoring Board or Advisory Board with Alcon Laboratories, Inc; Allergan, Inc; BELKIN Vision Ltd; Carl Zeiss Meditec; Elios and Visufarma; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with Glaucoma UK Medical Advisory Board and UK&Eire Glaucoma Society as president. M E Hartnett reports support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) from Michael F. Marmor, M.D. Professor of Retinal Science and Disease as endowment to support salary; grants or contracts from any entity (from National Eye Institute R01 EY017011 and National Eye Institute R01 EY015130) as partial salary support; patents planned, issued or pending (WO2015123561A2 and WO2021062169A1); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with Jack McGovern Coats' Disease Foundation and as director of Women's Eye Health and Macular Society Grant Review Chair. J H Kempen reports support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) from Mass Eye and Ear Global Surgery Program (as support of salary). J E Kim reports consulting fees from Genentech/Roche, DORC, Notal Vision and Outlook Therapeutics (all as payment to J E Kim); participation on a Data Safety Monitoring Board or Advisory Board with Allergan, Amgen, Apellis, Bausch&Lomb, Clearside, Coherus, Novartis and Regeneron (all as participation on advisory board); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with AAO, APRIS, ASRS, Macular Society and NAEVR/AEVR (all unpaid); and receipt of equipment, materials, drugs, medical writing, gifts or other services from Clearside and Genentech/Roche (both for medical writing). V C Lansingh reports consulting fees from HelpMeSee (as an employee); and support for attending meetings and/or travel from HelpMeSee (pay airfare and hotel). J Leasher reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with National Eye Institute (as a member) and National Eye Health Education Program planning committee (unpaid). K S Naidoo reports other financial or non-financial interests from OneSight Essilor Luxottica Foundation as an employee of the non-profit foundation. M Nowak reports participation on a Data Safety Monitoring Board or Advisory Board with Vision Express Co. Poland as the chairman of medical advisory board of Vision Express Co. Poland. P Ramulu reports

grants or contracts from National Institute of Health and Perfuse Therapeutics; and consulting fees from Alcon and W. L. Gore. F Topouzis reports grants or contracts from Théa, Omikron, Pfizer, Alcon, Abbvie and Bayer (all paid to Institution); consulting fees from Omikron, Théa and Bausch & Lomb (all paid to Topouzis); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Omikron (paid to Topouzis), Abbvie and Roche (both paid to Institution); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with European Glaucoma Society (as president), Greek Glaucoma Society (as president) and Board of Governors, World Glaucoma Association (all unpaid).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41433-024-03106-0>.

Correspondence and requests for materials should be addressed to .

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

VISION LOSS EXPERT GROUP OF THE GLOBAL BURDEN OF DISEASE STUDY

Julie-Anne Little^{1,2,13,14}, Nathan G. Congdon^{2,3,4}, Serge Resnikoff^{5,6}, Tasanee Braithwaite^{7,8}, Janet Leasher⁹, Kovin Naidoo^{10,11}, Tim Fricke^{12,13,14}, Ian Tapply¹⁵, Arthur G. Fernandes^{16,17}, Maria Vittoria Cicinelli^{18,19}, Alessandro Arrigo²⁰, Nicolas Leveziel^{21,22}, Hugh R. Taylor²³, Tabassom Sedighi²⁴, Seth Flaxman²⁵, Maurizio Battaglia Parodi²⁶, Mukkharrem M. Bikbov²⁷, Alain Bron²⁸, Ching-Yu Cheng^{29,30}, Monte A. Del Monte^{31,32}, Joshua R. Ehrlich^{33,34}, Leon B. Ellwein³⁵, David Friedman³⁶, João M. Furtado³⁷, Gus Gazzard³⁸, Ronnie George³⁹, M. Elizabeth Hartnett⁴⁰, Jost B. Jonas⁴¹, Rim Kahloun⁴², John H. Kempen^{43,44,45,46}, Moncef Khairallah⁴⁷, Rohit C. Khanna^{11,48,49,50}, Judy E. Kim⁵¹, Van Charles Lansingh^{52,53,54}, Vinay Nangia⁵⁵, Michal Nowak⁵⁶, Konrad Pesudovs⁵⁷, Tunde Peto⁵⁸, Pradeep Ramulu⁵⁹, Fotis Topouzis⁶⁰, Mitidias Tsilimbaris⁶¹, Ya Xing Wang⁶², Ningli Wang⁶³ and Rupert R. A. Bourne²⁴

¹Biomedical Sciences Research Institute, Ulster University, Coleraine BT52 1SA, UK. ²Queen's University Belfast, Northern Ireland, UK. ³Orbis International, New York, USA. ⁴Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. ⁵Brien Holden Vision Institute, Sydney, NSW, Australia. ⁶School of Optometry and Vision Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. ⁷School of Life Course and Population Sciences, King's College London, London, UK. ⁸The Medical Eye Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁹Nova Southeastern University College for Optometry, Fort Lauderdale, Florida, USA. ¹⁰African Vision Research Institute, University of KwaZulu-Natal (UKZN), Durban, South Africa. ¹¹School of Optometry and Vision Science, University of New South Wales, Sydney, Australia. ¹²Australian College of Optometry, Vic, Australia. ¹³University of Melbourne, Vic, Australia. ¹⁴UNSW Sydney, Sydney, NSW, Australia. ¹⁵Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK. ¹⁶Federal University of Sao Paulo, Sao Paulo/SP, Brazil. ¹⁷University of Calgary, Calgary/AB, Canada. ¹⁸School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. ¹⁹Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy. ²⁰Scientific Institute San Raffaele Hospital, Vita-Salute University, Milan, Italy. ²¹University of Poitiers, Poitiers, France. ²²CHU de Poitiers, Poitiers, France. ²³School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia. ²⁴Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK. ²⁵Department of Computer Science, University of Oxford, Oxford, UK. ²⁶Department of Ophthalmology, Vita-Salute San Raffaele University, Milano, Italy. ²⁷Ufa Eye Research Institute, Ufa, Russia. ²⁸University Hospital, Dijon, France. ²⁹National University of Singapore, Singapore, Singapore. ³⁰Singapore Eye Research Institute, Singapore, Singapore. ³¹University of Michigan, Singapore, Singapore. ³²Kellogg Eye Center, Ann Arbor MI 48105, USA. ³³Institute for Social Research, University of Michigan, Michigan, USA. ³⁴Department of Ophthalmology and Visual Sciences, University of Michigan, Michigan, USA. ³⁵National Eye Institute, Bethesda, MD, USA. ³⁶Mass Eye and Ear, Harvard Medical School, Boston MA 02115, USA. ³⁷Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. ³⁸Institute of Ophthalmology UCL & NIHR Biomedical Research Centre, Bethesda, MD, USA. ³⁹Sankara Nethralaya, Medical Research Foundation, Chennai 600006, India. ⁴⁰Stanford University, Stanford CA 94305, USA. ⁴¹Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany. ⁴²Associated Ophthalmologists of Monastir, Monastir, Tunisia. ⁴³Department of Ophthalmology, Harvard University, Boston, MA, USA. ⁴⁴Eye Unit, MyungSung Medical College, Addis Ababa, Ethiopia. ⁴⁵Department of Ophthalmology, Addis Ababa University, Addis Ababa, Ethiopia. ⁴⁶Sight for Souls, Bellevue, WA, USA. ⁴⁷Fattouma Bourguiba University Hospital,

University of Monastir, Monastir 5000, Tunisia. ⁴⁸Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye care, L.V. Prasad Eye Institute, Hyderabad, India. ⁴⁹Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Banjara Hills, Hyderabad, India. ⁵⁰University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA. ⁵¹University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. ⁵²HelpMeSee, Instituto Mexicano de Oftalmologia, New York, NY 10018-8005, USA. ⁵³University of Miami, Coral Gables, FL 33146, USA. ⁵⁴University of Utah, Salt Lake City, UT 84112, USA. ⁵⁵Suraj Eye Institute, 559, New colony, Nagpur, India. ⁵⁶Institute of Optics and Optometry, University of Social Science, 121 Gdanska str., Lodz 90-519, Poland. ⁵⁷Medicine & Health, University of New South Wales, Sydney, NSW, Australia. ⁵⁸Centre for Public Health, Queens University Belfast, Northern Ireland, Belfast BT15 1ED, UK. ⁵⁹John Hopkins Wilmer Eye Institute, Baltimore, USA. ⁶⁰1st Department of Ophthalmology, Medical School, Aristotle University of Thessaloniki, Ahepa Hospital, Thessaloniki 546 36, Greece. ⁶¹University of Crete Medical School, Gíofrakia 715 00, Greece. ⁶²Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China. ⁶³Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. ⁶⁴email: ja.little@ulster.ac.uk

THE GBD 2019 BLINDNESS AND VISION IMPAIRMENT COLLABORATORS

Julie-Anne Little⁶⁴, Nathan G. Congdon^{65,66}, Serge Resnikoff^{4,67}, Tasanee Braithwaite^{68,69}, Janet L. Leasher⁷⁰, Kevin S. Naidoo^{67,71}, Nina Tahhan⁶⁷, Timothy Fricke^{67,72}, Ian Tappay¹⁴, Arthur G. Fernandes⁷³, Maria Vittoria Cicinelli⁷⁴, Alessandro Arrigo⁷⁵, Nicolas Levezuel^{76,77}, Paul Svitol Briant⁷⁸, Theo Vos^{78,79}, Hugh R. Taylor²², Tabassom Sedighi²³, Seth Flaxman^{24,80}, Yohannes Habtegiorgis Abate⁸¹, Zahra Abbasi Dolatabadi⁸², Michael Abdelmassah⁸³, Mohammad Abdollahi^{84,85}, Ayele Mamo Abebe⁸⁶, Olumide Abiodun⁸⁷, Richard Gyan Aboagye⁸⁸, Woldu Aberhe Abbrha⁸⁹, Hiwa Abubaker Ali⁹⁰, Eman Abu-Gharbieh⁹¹, Salahdein Aburuz^{92,93}, Tadele Girum Girum Adal⁹⁴, Lawan Hassan Adamu⁹⁵, Nicola J. Adderley⁹⁶, Isaac Yeboah Addo^{97,98}, Tayo Alex Adekiya⁹⁹, Kishor Adhikari^{100,101}, Qorinah Estiningtyas Sakilah Adnani¹⁰², Saira Afzal^{103,104}, Shahin Aghamiri¹⁰⁵, Antonella Agodi¹⁰⁶, Williams Agyemang-Duah¹⁰⁷, Bright Opoku Ahinkorah¹⁰⁸, Aqeel Ahmad¹⁰⁹, Hooman Ahmadzadeh¹¹⁰, Ayman Ahmed^{111,112}, Haroon Ahmed¹¹³, Fares Alahdab¹¹⁴, Mohammed Albashtawy¹¹⁵, Mohammad T. AlBataineh¹¹⁶, Tsegaye Alemu^{117,118}, Ahmad Samir Alfaar^{119,120}, Fadwa Alhalaiaqi Naji Alhalaiaqi^{121,122}, Robert Kaba Alhassan¹²³, Abid Ali¹²⁴, Syed Shujait Shujait Ali¹²⁵, Louay Almidani^{126,127}, Kareem H. Alzoubi^{128,129}, Sofia Androudi¹³⁰, Rodrigo Anguita^{131,132}, Abhishek Anil^{133,134}, Anayochukwu Edward Anyasodor¹³⁵, Jalal Arabloo¹³⁶, Aleksandr Y. Aravkin^{78,79,137}, Damelash Areda^{138,139}, Akeza Awealom Asgedom¹⁴⁰, Mubarek Yesse Ashemo^{141,142}, Tahira Ashraf¹⁴³, Seyyed Shamsadin Athari¹⁴⁴, Bantalem Tilaye Tilaye Atinafu¹⁴⁵, Maha Moh'd Wahbi Atout¹⁴⁶, Alok Atreya¹⁴⁷, Haleh Ayatollahi^{136,148}, Ahmed Y. Azzam^{149,150}, Sara Bagherieh¹⁵¹, Ruhai Bai¹⁵², Atif Amin Baig¹⁵³, Freddie Bailey¹⁵⁴, Ovidiu Constantin Baltatu¹⁵⁵, Shirin Barati¹⁵⁶, Martina Barchitta¹⁵⁷, Mainak Bardhan¹⁵⁸, Till Winfried Bärnighausen^{159,160}, Amadou Barrow^{161,162}, Maurizio Battaglia Parodi¹⁶³, Nebiyu Simegnaw Bayileegn¹⁶⁴, Alemshet Yirga Berhie¹⁶⁵, Abhishek Bhadra¹⁶⁶, Akshaya Srikanth Srikanth Bhagavathula¹⁶⁷, Pankaj Bhardwaj^{168,169}, Sonu Bhaskar^{170,171}, Ajay Nagesh Bhat¹⁷², Gurjit Kaur Bhatti¹⁷³, Mukharram Bikbov¹⁷⁴, Marina G. Birck^{175,176}, Yasser Bustanji^{177,178}, Zahid A. Butt^{179,180}, Florentino Luciano Caetano dos Santos¹⁸¹, Vera L. A. Carneiro^{182,183}, Muthia Cenderadewi^{184,185}, Gashaw Sisay Chanie¹⁸⁶, Nicolas Cherbuin¹⁸⁷, Dinh-Toi Chu¹⁸⁸, Kaleb Coberly⁷⁸, Natália Cruz-Martins^{189,190}, Omid Dadras^{191,192}, Xiaochen Dai^{78,79}, Lalit Dandona^{78,193,194}, Rakhi Dandona^{78,79,193}, Ana Maria Dascalu^{195,196}, Anna Dastiridou^{197,198}, Tadesse Asmamaw Dejenie¹⁹⁹, Dessalegn Demeke²⁰⁰, Diriba Dereje²⁰¹, Nikolaos Dervenis^{202,203}, Vinoth Gnana Chellaiyan Devanbu²⁰⁴, Daniel Diaz^{205,206}, Mengistie Diress²⁰⁷, Thanh Chi Do²⁰⁸, Thao Huynh Phuong Do²⁰⁹, Arkadiusz Marian Dziedzic²¹⁰, Hisham Atan Edinur²¹¹, Joshua R. Ehrlich^{212,213}, Michael Ekholuenetale^{214,215}, Hala Rashad Elhabashy²¹⁶, Muhammed Elhadi²¹⁷, Mohammad Hassan Emamian²¹⁸, Mehdi Emamverdi²¹⁹, Azin Etemadimanesh²²⁰, Adeniyi Francis Fagbamigbe^{214,221}, Hossein Farrokhpour^{222,223}, Ali Fatehizadeh²²⁴, Alireza Feizkhan²²⁵, Lorenzo Ferro Desideri²²⁶, Getahun Fetensa²²⁷, Florian Fischer²²⁸, Ali Forouhari^{229,230}, João M. Furtado²³¹, Muktar A. Gadanya^{232,233}, Abhay Motiramji Gaidhane²³⁴, Aravind P. Gandhi²³⁵, Tilaye Gebru Gebi²³⁶, Mesfin Gebrehiwot²³⁷, Gebreamlak Gebremedhn Gebremeskel^{238,239}, Yibeltal Yismaw Gela²⁰⁷, Bardiya Ghaderi Yazdi²⁴⁰, Khalil Ghaseini Falavarjani²⁴¹, Fariba Ghassemi²⁴², Sherief Ghozy²⁴³, Ali Golchin^{244,245}, Mahaveer Golechha²⁴⁶, Pouya Goleij^{247,248}, Shi-Yang Guan²⁴⁹, Sapna Gupta²⁵⁰, Vivek Kumar Gupta²⁵¹, Rasool Haddadi²⁵², Teklehaimanot Gereziher Haile²³⁸, Billy Randall Hammond²⁵³, Mehdi Harorani²⁵⁴, Ahmed I. Hasaballah²⁵⁵, Ikramul Hasan²⁵⁶, Hamidreza Hasani²⁵⁷, Hossein Hassanian-Moghaddam^{258,259}, Golnaz Heidari²⁶⁰, Demisu Zenbaba Heyi²⁶¹, Ramesh Holla²⁶², Mehdi Hosseinzadeh^{263,264}, Chengxi Hu²⁶⁵, Hong-Han Huynh²⁶⁶, Bing-Fang Hwang^{267,268}, Ivo Iavicoli²⁶⁹, Irena M. Ilic²⁷⁰, Mustapha Immurana¹²³, Sheikh Mohammed Shariful Islam^{271,272}, Louis Jacob^{273,274}, Abdullah Jafarzadeh^{275,276}, Mihajlo Jakovljevic^{277,278}, Manthan Dilipkumar Janodia²⁷⁹, Sathish Kumar Jayapal²⁸⁰, Shubha Jayaram²⁸¹, Jost B. Jonas^{282,283}, Nitin Joseph²⁸⁴, Charity Ehimwenma Joshua²⁸⁵, Sagarika Kamath²⁸⁶, Himal Kandel^{287,288}, Ibraheem M. Karaye^{289,290}, Hengameh Kasraei^{241,291}, Soujanya Kaup²⁹², Harkiran Kaur²⁹³, Navjot Kaur²⁹⁴, Gbenga A. Kayode^{295,296}, John H. Kempen^{42,43}, Yousef Saleh Khader²⁹⁷, Himanshu Khajuria²⁹⁸, Rovshan Khalilov^{299,300}, Ajmal Khan³⁰¹, Moawiah Mohammad Khatatbeh³⁰², Mahalaqua Nazli Khatib³⁰³, Biruk Getahun Kibret³⁰⁴, Yun Jin Kim³⁰⁵, Adnan Kisa^{306,307}, Sezer Kisa³⁰⁸, Soewarta Kosen³⁰⁹, Ai Koyanagi³¹⁰, Kewal Krishan³¹¹, Burcu Kucuk Bicer³¹², Nithin Kumar²⁸⁴, L. V. Simhachalam Kutikuppala³¹³, Chandrakant Lahariya^{314,315}, Tri Laksono^{316,317}, Dharmesh Kumar Lal¹⁹³, Van Charles Lansingh^{318,319}, Munjee Lee³²⁰, Seung Won Lee³²¹, Wei-Chen Lee³²², Stephen S. Lim^{78,79}, Xuefeng Liu^{323,324}, Sandeep B. Maharaj^{325,326}, Alireza Mahmoudi³²⁷, Kashish Malhotra³²⁸, Ahmad Azam Malik^{153,329}, Iram Malik³³⁰, Tauqeer Hussain Mallhi³³¹, Vahid Mansouri³³², Roy Rillera Marzo^{333,334}, Andrea Maugeri¹⁵⁷, Gebrekiros Gebremichael Meles³³⁵, Abera M. Mersha³³⁶, Tomislav Mestrovic^{78,337}, Ted R. Miller^{338,339}, Mehdi Mirzaei³⁴⁰, Awoke Misganaw^{79,341}, Sanjeev Misra³⁴², Prasanna Mithra²⁸⁴, Soheil Mohammadi²²², Abdollah Mohammadian-Hafshejani³⁴³, Maryam Mohammadzadeh³⁴⁴, Hoda Mojiri-forushani³⁴⁵, Ali H. Mokdad^{78,79}, Hamed Momeni-Moghaddam^{346,347}, Fateme Montazeri^{348,349}, Maryam Moradi³⁵⁰, Parsa Mousavi³⁴⁸, Christopher J. L. Murray^{78,79}, Ganesh R. Naik^{351,352}, Gurudatta Naik³⁵³, Zuhair S. Natto^{354,355}, Muhammad Naveed³⁵⁶, Biswa Prakash Nayak²⁹⁸, Hadush Negash³⁵⁷, Seyed Aria Nejadghaderi^{349,358}, Dang H. Nguyen^{359,360}, Duc Hoang Nguyen^{361,362}, Hien Quang Nguyen³⁶³, Phat Tuan Nguyen³⁶⁴, Van Thanh Nguyen³⁶⁵, Robina Khan Niazi³⁶⁶, Efaq Ali Noman^{367,368}, Bogdan Oancea³⁶⁹, Osaretin Christabel Okonji³⁷⁰, Andrew T. Olagunju^{371,372}, Isaac Iyinoluwa Olufadewa^{215,373}, Obinna E. Onwujekwe³⁷⁴, Abdulahi Opejin Opejin³⁷⁵, Michal Ordak³⁷⁶, Uchechukwu Levi Osuagwu^{377,378}, Nikita Ostavnov³⁷⁹,

Mayowa O. Owolabi^{380,381}, Jagadish Rao Padubidri³⁸², Songhomitra Panda-Jonas³⁸³, Anamika Pandey¹⁹³, Shahina Pardhan²³, Amirhossein Parsaei³⁴⁸, Jay Patel^{384,385}, Shrikant Pawar³⁸⁶, Arokiasamy Perianayagam³⁸⁷, Navaraj Perumalsamy^{388,389}, Konrad Pesudovs⁶⁷, Ionela-Roxana Petcu³⁹⁰, Hoang Tran Pham³⁹¹, Mohsen Pourazizi¹²²⁹, Elton Junio Sady Prates³⁹², Ibrahim Qattea³⁹³, Pankaja Raghav Raghav¹⁶⁸, Mohammad Hifz Ur Rahman³⁹⁴, Mosiur Rahman³⁹⁵, Shakthi Kumaran Ramasamy³⁹⁶, Premkumar Ramasubramani³⁹⁷, Mohammad-Mahdi Rashidi^{258,348}, Elrashdy Moustafa Mohamed Redwan^{398,399}, Nazila Rezaei³⁴⁸, Jefferson Antonio Buendia Rodriguez^{400,401}, Zahra Saadati^{402,403}, Siamak Sabour⁴⁰⁴, Basema Saddik⁴⁰⁵, Umar Saeed^{406,407}, Sare Saffi^{408,409}, Amene Saghzadeh⁴¹⁰, Fatemeh Saheb Sharif-Askari⁴¹¹, Narjes Saheb Sharif-Askari⁴¹², Amirhossein Sahebkar^{413,414}, Mohammad Ali Sahraian⁴¹⁵, Joseph W. Sakshaug^{416,417}, Mohamed A. Saleh^{418,419}, Sara Samadzadeh^{420,421}, Yoseph Leonardo Samodra^{422,422}, Abdallah M. Samy^{423,424}, Mete Saylan⁴²⁵, Siddharthan Selvaraj⁴²⁶, Yashendra Sethi⁴²⁷, Allen Seylani⁴²⁸, Moyad Jamal Shahwan⁴²⁹, Masood Ali Shaikh⁴³⁰, Muhammad Aaqib Shamim¹³³, Bereket Beyene Shashamo³³⁶, Wondimeneh Shibabaw Shiferaw⁴³¹, Mika Shigematsu⁴³², Aminu Shittu⁴³³, Parnian Shobeiri^{434,435}, Seyed Afshin Shorofi^{436,437}, Migbar Mekonnen Sibhat⁴³⁸, Emmanuel Edwar Siddig^{439,440}, Juan Carlos Silva⁴⁴¹, Jasvinder A. Singh^{442,443}, Paramdeep Singh⁴⁴⁴, Houman Sotoudeh⁴⁴⁵, Raúl A. R. C. Sousa⁴⁴⁶, Chandrashekhar T. Sreeramareddy⁴⁴⁷, Mohammad Tabish⁴⁴⁸, Majid Taheri^{449,450}, Yao Tan⁴⁵¹, Birhan Tsegaw Taye¹⁴⁵, Mohamad-Hani Temsah⁴⁵², Jansje Henry Vera Ticoalu⁴⁵³, Tala Tillawi⁴⁵⁴, Misganaw Guadie Tiruneh⁴⁵⁵, Aristidis Tsatsakis⁴⁵⁶, Guesh Mebrahtom Tsegay²³⁸, Miltiadis K. Tsilimbaris⁴⁵⁷, Sree Sudha Ty⁴⁵⁸, Chukwudi S. Ubah^{459,460}, Muhammad Umair^{461,462}, Sahel Valadan Tahbaz^{463,464}, Rohollah Valizadeh⁴⁶⁵, Maria Viskadourou⁴⁶⁶, Gizachew Tadesse Wassie⁴⁶⁷, Nuwan Darshana Wickramasinghe⁴⁶⁸, Guadie Sharew Wondimaginegn^{469,470}, Galal Yahya^{471,472}, Lin Yang^{473,474}, Yao Yao^{475,476}, Arzu Yigit⁴⁷⁷, Yazachew Yismaw^{478,479}, Naohiro Yonemoto^{480,481}, Yuyi You^{287,340}, Mikhail Sergeevich Zastrozhin^{482,483}, Getachew Assefa Zenebe⁴⁸⁴, Zhi-Jiang Zhang⁴⁸⁵, Hanqing Zhao⁴⁸⁶, Magdalena Zielińska⁴⁸⁷, Mohammad Zoladl⁴⁸⁸, Jaimie D. Steinmetz⁷⁸ and Rupert Bourne²³

⁶⁴School of Biomedical Sciences, Ulster University, Coleraine, UK. ⁶⁵Centre for Public Health, Queen's University, Belfast, UK. ⁶⁶ORBIS International, New York, NY, USA. ⁶⁷School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia. ⁶⁸Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK. ⁶⁹International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. ⁷⁰College of Optometry, Nova Southeastern University, Fort Lauderdale, FL, USA. ⁷¹Discipline of Optometry, University of KwaZulu-Natal, Durban, South Africa. ⁷²Department of Optometry and Vision Sciences, University of Melbourne, Melbourne, VIC, Australia. ⁷³Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, Brazil. ⁷⁴Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy. ⁷⁵Scientific Institute San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. ⁷⁶Ophthalmology Department, CHU de Poitiers (Poitiers University Hospital), Poitiers, France. ⁷⁷Unité 1084, National Institute of Health and Medical Research (INSERM), Poitiers, France. ⁷⁸Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ⁷⁹Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ⁸⁰Department of Mathematics, Imperial College London, London, UK. ⁸¹Department of Clinical Governance and Quality Improvement, Aleta Wondo Hospital, Aleta Wondo, Ethiopia. ⁸²Department of Medical-Surgical Nursing, Tehran University of Medical Sciences, Tehran, Iran. ⁸³Department of Surgery, Marshall University, Huntington, WV, USA. ⁸⁴The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. ⁸⁵School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ⁸⁶Pediatrics Nursing Department, Debre Berhan University, Debre Berhan, Ethiopia. ⁸⁷Department of Community Medicine, Babcock University, Ilishan-Remo, Nigeria. ⁸⁸Department of Family and Community Health, University of Health and Allied Sciences, Ho, Ghana. ⁸⁹Department of Adult Health Nursing, Aksum University, Aksum, Ethiopia. ⁹⁰Department of Banking and Finance, University of Human Development, Sulaymaniyah, Iraq. ⁹¹Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates. ⁹²Department of Therapeutics, United Arab Emirates University, Al Ain, United Arab Emirates. ⁹³College of Pharmacy, University of Jordan, Amman, Jordan. ⁹⁴Department of Public Health, Wolkite University, Wolkite, Ethiopia. ⁹⁵Department of Human Anatomy, Federal University Dutse, Dutse, Nigeria. ⁹⁶Institute of Applied Health Research, University of Birmingham, Birmingham, UK. ⁹⁷Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia. ⁹⁸Quality and Systems Performance Unit, Cancer Institute NSW, Sydney, NSW, Australia. ⁹⁹Department of Pharmaceutical Sciences, Howard University, Washington, DC, USA. ¹⁰⁰School of Public Health, Chitwan Medical College and Teaching Hospital, Bharatpur, Nepal. ¹⁰¹Public Health Section, Himalayan Environment and Public Health Network (HEPHN), Chitwan, Nepal. ¹⁰²Faculty of Medicine, Padjadjaran University, Bandung, Indonesia. ¹⁰³Department of Community Medicine, King Edward Memorial Hospital, Lahore, Pakistan. ¹⁰⁴Department of Public Health, Public Health Institute, Lahore, Pakistan. ¹⁰⁵Department of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹⁰⁶Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy. ¹⁰⁷Department of Geography and Planning, Queen's University, Kingston, ON, Canada. ¹⁰⁸School of Public Health, University of Technology Sydney, Sydney, NSW, Australia. ¹⁰⁹Department of Medical Biochemistry, Shaqra University, Shaqra, Saudi Arabia. ¹¹⁰Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA. ¹¹¹Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. ¹¹²Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland. ¹¹³Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan. ¹¹⁴Evidence-Based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA. ¹¹⁵Community and Mental Health Department, Al al-Bayt University, Mafrq, Jordan. ¹¹⁶Department of Molecular Biology and Genetics, Khalifa University, Abu Dhabi, United Arab Emirates. ¹¹⁷Department of Public Health, Hawassa University, Hawassa, Ethiopia. ¹¹⁸Department of Public Health, Ministry of Health (MOH), Hawassa, Ethiopia. ¹¹⁹Department of Ophthalmology, University of Leipzig Medical Center, Leipzig, Germany. ¹²⁰Department of Ophthalmology, Charité Medical University Berlin, Berlin, Germany. ¹²¹College of Nursing, Qatar University, Doha, Qatar. ¹²²Psychological Sciences Association, Amman, Jordan. ¹²³Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana. ¹²⁴Department of Zoology, Abdul Wali Khan University Mardan, Mardan, Pakistan. ¹²⁵Center for Biotechnology and Microbiology, University of SWAT, Swat, Pakistan. ¹²⁶Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹²⁷Doheny Image Reading and Research Lab (DIRRL), University of California Los Angeles, Los Angeles, CA, USA. ¹²⁸Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates. ¹²⁹Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. ¹³⁰Department of Medicine, University of Thessaly, Volos, Greece. ¹³¹Department of Ophthalmology, Inselspital, Bern, Switzerland. ¹³²Department of Vitreoretinal, Moorfields Eye Hospital, London, UK. ¹³³Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. ¹³⁴All India Institute of Medical Sciences, Bhubaneswar, India. ¹³⁵School of Dentistry and Medical Sciences, Charles Sturt University, Orange, NSW, Australia. ¹³⁶Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ¹³⁷Department of Applied Mathematics, University of Washington, Seattle, WA, USA. ¹³⁸College of Art and Science, Ottawa University, Surprise, AZ, USA. ¹³⁹School of Life Sciences, Arizona State University, Tempe, AZ, USA. ¹⁴⁰Department of Environmental Health, Mekelle University, Mekelle, Ethiopia. ¹⁴¹Department of Public Health, Jimma University, Jimma, Ethiopia. ¹⁴²Department of Public Health, Wachemo University, Hossana, Ethiopia. ¹⁴³University Institute of Radiological Sciences and Medical Imaging Technology, The University of Lahore, Lahore, Pakistan. ¹⁴⁴Department of Immunology, Zanjan University of Medical Sciences, Zanjan, Iran. ¹⁴⁵School of Nursing and Midwifery, Debre Berhan University, Debre Berhan, Ethiopia. ¹⁴⁶Faculty of Nursing, Philadelphia University, Amman, Jordan. ¹⁴⁷Department of Forensic Medicine, Lumbini Medical College, Palpa, Nepal. ¹⁴⁸Department of Health Information Management, Iran University of Medical Sciences, Tehran, Iran. ¹⁴⁹Department of Neurovascular Research, Nested Knowledge, Inc., Saint Paul, MN, USA. ¹⁵⁰Faculty of Medicine, October 6 University, 6th of October City, Giza Governorate, Egypt. ¹⁵¹School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁵²School of Public Affairs, Nanjing University of Science and Technology, Nanjing, China. ¹⁵³University Institute of Public Health, The University of Lahore, Lahore, Pakistan. ¹⁵⁴Big Data Institute - GRAM Project, University of Oxford, Oxford, UK. ¹⁵⁵Center of Innovation, Technology and Education (CITE), Anhembi Morumbi University, São Jose dos Campos, Brazil. ¹⁵⁶Department of Anatomy, Saveh University of Medical Sciences, Saveh, Iran. ¹⁵⁷Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Catania, Italy. ¹⁵⁸Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. ¹⁵⁹Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany. ¹⁶⁰T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. ¹⁶¹Department of Epidemiology, University of Florida, Gainesville, FL, USA. ¹⁶²Department of Public & Environmental Health, University of The Gambia, Brikama, The Gambia. ¹⁶³Department of Ophthalmology,

Vita-Salute San Raffaele University, Milan, Italy. ¹⁶⁴Department of Surgery, Jimma University, Jimma, Ethiopia. ¹⁶⁵School of Health Science, Bahir Dar University, Bahir Dar, Ethiopia. ¹⁶⁶Department of Pharmacology, Popular Medical College, Dhaka, Bangladesh. ¹⁶⁷Department of Public Health, North Dakota State University, Fargo, ND, USA. ¹⁶⁸Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ¹⁶⁹School of Public Health, All India Institute of Medical Sciences, Jodhpur, India. ¹⁷⁰Global Health Neurology Lab, NSW Brain Clot Bank, Sydney, NSW, Australia. ¹⁷¹Department of Neurology and Neurophysiology, South West Sydney Local Health District and Liverpool Hospital, Sydney, NSW, Australia. ¹⁷²Department of General Medicine, Manipal Academy of Higher Education, Mangalore, India. ¹⁷³Medical Lab Technology, Chandigarh University, Mohali, India. ¹⁷⁴Epidemiology Department, Ufa Eye Research Institute, Ufa, Russia. ¹⁷⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada. ¹⁷⁶Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. ¹⁷⁷Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan. ¹⁷⁸Department of Basic Biomedical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ¹⁷⁹School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. ¹⁸⁰Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan. ¹⁸¹Harvard Business School, Harvard University, Boston, MA, USA. ¹⁸²School of Sciences, University of Minho, Braga, Portugal. ¹⁸³Association of Licensed Optometry Professionals, Linda-a-Velha, Portugal. ¹⁸⁴College of Public Health, James Cook University, Townsville, QLD, Australia. ¹⁸⁵Department of Public Health, University of Mataram, Mataram, Indonesia. ¹⁸⁶Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia. ¹⁸⁷Research School of Population Health, Australian National University, Canberra, ACT, Australia. ¹⁸⁸Center for Biomedicine and Community Health, VNU-International School, Hanoi, Vietnam. ¹⁸⁹Therapeutic and Diagnostic Technologies, Cooperativa de Ensino Superior Politécnico e Universitário (Polytechnic and University Higher Education Cooperative), Gandra, Portugal. ¹⁹⁰Institute for Research and Innovation in Health, University of Porto, Porto, Portugal. ¹⁹¹Department of Addiction Medicine, Haukland University Hospital, Bergen, Norway. ¹⁹²Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. ¹⁹³Public Health Foundation of India, Gurugram, India. ¹⁹⁴Indian Council of Medical Research, New Delhi, India. ¹⁹⁵Ophthalmology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ¹⁹⁶Ophthalmology Department, Emergency University Hospital Bucharest, Bucuresti, Romania. ¹⁹⁷dummy2nd University Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. ¹⁹⁸Ophthalmology Department, University of Thessaly, Larissa, Greece. ¹⁹⁹Department of Medical Biochemistry, University of Gondar, Gondar, Ethiopia. ²⁰⁰Department of Physiology, Bahir Dar University, Bahir Dar, Ethiopia. ²⁰¹Department of Biomedical Sciences, Jimma University, Jimma, Ethiopia. ²⁰²St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. ²⁰³Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ²⁰⁴Department of Community Medicine, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chennai, India. ²⁰⁵Center of Complexity Sciences, National Autonomous University of Mexico, Mexico City, Mexico. ²⁰⁶Faculty of Veterinary Medicine and Zootechnics, Autonomous University of Sinaloa, Culiacán Rosales, Mexico. ²⁰⁷Department of Human Physiology, University of Gondar, Gondar, Ethiopia. ²⁰⁸Department of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. ²⁰⁹Department of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam. ²¹⁰Department of Conservative Dentistry with Endodontics, Medical University of Silesia, Katowice, Poland. ²¹¹School of Health Sciences, University of Science Malaysia, Kubang Kerian, Malaysia. ²¹²Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. ²¹³Institute for Health Care Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. ²¹⁴Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria. ²¹⁵Faculty of Public Health, University of Ibadan, Ibadan, Nigeria. ²¹⁶Neurophysiology Department, Cairo University, Cairo, Egypt. ²¹⁷Faculty of Medicine, University of Tripoli, Tripoli, Libya. ²¹⁸Ophthalmic Epidemiology Research Center, Shahrud University of Medical Sciences, Shahrud, Iran. ²¹⁹Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA. ²²⁰Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD, USA. ²²¹Research Centre for Healthcare and Community, Coventry University, Coventry, UK. ²²²School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ²²³Endocrinology and Metabolism Research Institute, Non-Communicable Diseases Research Center, Tehran, Iran. ²²⁴Department of Environmental Health Engineering, Isfahan University of Medical Sciences, Isfahan, Iran. ²²⁵Department of Social Medicine and Epidemiology, Guilan University of Medical Sciences, Rasht, Iran. ²²⁶University Eye Clinic, University of Genoa, Genoa, Italy. ²²⁷Department of Nursing, Wollega University, Nekemte, Ethiopia. ²²⁸Institute of Public Health, Charité Medical University Berlin, Berlin, Germany. ²²⁹Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. ²³⁰Emergency Department, Isfahan University of Medical Sciences, Isfahan, Iran. ²³¹Division of Ophthalmology, University of São Paulo, Ribeirão Preto, Brazil. ²³²Community Medicine Department, Bayero University, Kano, Kano, Nigeria. ²³³Department of Community Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria. ²³⁴Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India. ²³⁵Department of Community Medicine, ESIC Medical College & Hospital, Hyderabad, India. ²³⁶Health Sciences Department of Oncology Nursing, Haramaya University, Harar, Ethiopia. ²³⁷Department of Environmental Health, Wollo University, Dessie, Ethiopia. ²³⁸Department of Nursing, Aksum University, Aksum, Ethiopia. ²³⁹Department of Nursing, Mekelle University, Mekelle, Ethiopia. ²⁴⁰Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran. ²⁴¹Eye Research Center, Iran University of Medical Sciences, Tehran, Iran. ²⁴²Ophthalmology Department, Tehran University of Medical Sciences, Tehran, Iran. ²⁴³Department of Radiology, Mayo Clinic, Rochester, MN, USA. ²⁴⁴Department of Applied Cell Sciences, Urmia University of Medical Sciences, Urmia, Iran. ²⁴⁵Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. ²⁴⁶Health Systems and Policy Research Department, Indian Institute of Public Health, Gandhinagar, India. ²⁴⁷Department of Genetics, Sana Institute of Higher Education, Sari, Iran. ²⁴⁸Universal Scientific Education and Research Network (USERN), Kermanshah University of Medical Sciences, Kermanshah, Iran. ²⁴⁹Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China. ²⁵⁰Toxicology Department, Shriram Institute for Industrial Research, Delhi, India. ²⁵¹Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. ²⁵²Department of Pharmacology and Toxicology, Hamadan University of Medical Sciences, Hamadan, Iran. ²⁵³Brain and Behavioral Sciences Program, University of Georgia, Athens, GA, USA. ²⁵⁴Department of Nursing, Arak University of Medical Sciences, Arak, Iran. ²⁵⁵Department of Zoology and Entomology, Al Azhar University, Cairo, Egypt. ²⁵⁶Department of Pharmaceutical Technology, University of Dhaka, Dhaka, Bangladesh. ²⁵⁷Department of Ophthalmology, Iran University of Medical Sciences, Karaj, Iran. ²⁵⁸Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁵⁹Chapter of Addiction Medicine, University of Sydney, Sydney, NSW, Australia. ²⁶⁰Independent Consultant, Santa Clara, CA, USA. ²⁶¹Department of Public Health, Madda Walabu University, Robe, Ethiopia. ²⁶²Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. ²⁶³Institute of Research and Development, Duy Tan University, Da Nang, Vietnam. ²⁶⁴Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq. ²⁶⁵Department of Psychology, Tsinghua University, Beijing, China. ²⁶⁶School of Biotechnology, Tan Tao University, Long An, Vietnam. ²⁶⁷Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan. ²⁶⁸Department of Occupational Therapy, Asia University, Taiwan, Taichung, Taiwan. ²⁶⁹Department of Public Health, University of Naples Federico II, Naples, Italy. ²⁷⁰Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ²⁷¹Institute for Physical Activity and Nutrition, Deakin University, Burwood, VIC, Australia. ²⁷²Sydney Medical School, University of Sydney, Sydney, NSW, Australia. ²⁷³Research and Development Unit, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Sant Boi de Llobregat, Spain. ²⁷⁴Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le Bretonneux, France. ²⁷⁵Department of Immunology, Kerman University of Medical Sciences, Kerman, Iran. ²⁷⁶Department of Immunology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ²⁷⁷Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia. ²⁷⁸Institute of Comparative Economic Studies, Hosei University, Tokyo, Japan. ²⁷⁹Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. ²⁸⁰Centre of Studies and Research, Ministry of Health, Muscat, Oman. ²⁸¹Department of Biochemistry, Government Medical College, Mysuru, India. ²⁸²Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. ²⁸³Department of Ophthalmology, Heidelberg University, Mannheim, Germany. ²⁸⁴Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India. ²⁸⁵Department of Economics, National Open University, Benin City, Nigeria. ²⁸⁶Manipal Institute of Management, Manipal Academy of Higher Education, Manipal, India. ²⁸⁷Save Sight Institute, University of Sydney, Sydney, NSW, Australia. ²⁸⁸Sydney Eye Hospital, South Eastern Sydney Local Health District, Sydney, NSW, Australia. ²⁸⁹School of Health Professions and Human Services, Hofstra University, Hempstead, NY, USA. ²⁹⁰Department of Anesthesiology, Montefiore Medical Center, Bronx, NY, USA. ²⁹¹Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ²⁹²Department of Ophthalmology, Yenepoya Medical College, Mangalore, India. ²⁹³Public Health Foundation of India, New Delhi, India. ²⁹⁴Department of ENT, Dr. B. R. Ambedkar State Institute of Medical Sciences (AIMS), Mohali, India. ²⁹⁵International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria. ²⁹⁶Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands. ²⁹⁷Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan. ²⁹⁸Amity Institute of Forensic Sciences, Amity University, Noida, India. ²⁹⁹Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan. ³⁰⁰Azerbaijan State University of Economics (UNEC), Baku, Azerbaijan. ³⁰¹Natural and Medical Sciences Research Center, University of Nizwa, Oman, Nizwa, Oman. ³⁰²Department of Basic Medical Sciences, Yarmouk University, Irbid, Jordan. ³⁰³Global Consortium for Public Health Research, Datta Meghe Institute of Higher Education and Research, Wardha, India. ³⁰⁴Department of Medical Physiology, Bahir Dar University, Bahir Dar, Ethiopia. ³⁰⁵School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia. ³⁰⁶School of Health Sciences, Kristiania University College, Oslo, Norway. ³⁰⁷Department of International Health and Sustainable Development, Tulane University, New Orleans, LA, USA. ³⁰⁸Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway. ³⁰⁹Independent Consultant, Jakarta, Indonesia. ³¹⁰San Juan de Dios Sanitary Park, Barcelona, Spain. ³¹¹Department of Anthropology, Panjab University, Chandigarh, India. ³¹²Faculty of Medicine, Gazi University, Ankara, Türkiye. ³¹³Department of

General Surgery, Dr NTR University of Health Sciences, Vijayawada, India. ³¹⁴Department of Health Policy and Strategy, Foundation for People-centric Health Systems, New Delhi, India. ³¹⁵SD Gupta School of Public Health, Indian Institute of Health Management Research University, Jaipur, India. ³¹⁶Department of Physiotherapy, Universitas Aisyiyah Yogyakarta, Yogyakarta, Indonesia. ³¹⁷Institute of Allied Health Sciences, National Cheng Kung University, Tainan, Taiwan. ³¹⁸Chief Medical Office, HelpMeSee, New York, NY, USA. ³¹⁹Mexican Institute of Ophthalmology, Queretaro, Mexico. ³²⁰Department of Medical Science, Ajou University School of Medicine, Suwon, South Korea. ³²¹Department of Precision Medicine, Sungkyunkwan University, Suwon, South Korea. ³²²Department of Internal Medicine, University of Texas, Galveston, TX, USA. ³²³Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ³²⁴Department of Quantitative Health Science, Case Western Reserve University, Cleveland, OH, USA. ³²⁵School of Pharmacy, University of the West Indies, St. Augustine, Trinidad and Tobago. ³²⁶Fellow, Planetary Health Alliance, Boston, MA, USA. ³²⁷Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran. ³²⁸Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India. ³²⁹Rabigh Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. ³³⁰Electrical Engineering Department, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia. ³³¹Department of Clinical Pharmacy, Jof University, Sakaka, Saudi Arabia. ³³²Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. ³³³Department of Public Health, Management and Science University, Shah Alam, Malaysia. ³³⁴Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia. ³³⁵School of Public Health, Mekelle University, Mekelle, Ethiopia. ³³⁶Department of Nursing, Arba Minch University, Arba Minch, Ethiopia. ³³⁷University Centre Varazdin, University North, Varazdin, Croatia. ³³⁸Pacific Institute for Research & Evaluation, Calverton, MD, USA. ³³⁹School of Public Health, Curtin University, Perth, WA, Australia. ³⁴⁰Macquarie Medical School, Macquarie University, Sydney, NSW, Australia. ³⁴¹National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. ³⁴²Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India. ³⁴³Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran. ³⁴⁴Translational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁴⁵Department of Pharmacology, Abadan School of Medical Sciences, Abadan, Iran. ³⁴⁶Department of Optometry and Vision Sciences, Zahedan University of Medical Sciences, Zahedan, Iran. ³⁴⁷Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ³⁴⁸Non-Communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁴⁹School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁵⁰Iran University of Medical Sciences, Tehran, Iran. ³⁵¹College of Medicine and Public Health, Flinders University, Adelaide, Australia. ³⁵²Department of Engineering, Western Sydney University, Sydney, NSW, Australia. ³⁵³Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. ³⁵⁴Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia. ³⁵⁵Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA. ³⁵⁶Department of Biotechnology, University of Central Punjab, Lahore, Pakistan. ³⁵⁷Department of Medical Laboratory Sciences, Adigrat University, Adigrat, Ethiopia. ³⁵⁸Department of Epidemiology, Non-Communicable Diseases Research Center, Tehran, Iran. ³⁵⁹Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA. ³⁶⁰Department of Medical Engineering, University of South Florida, Tampa, FL, USA. ³⁶¹Cardiovascular Laboratory, Methodist Hospital, Merrillville, Merrillville, IN, USA. ³⁶²Department of Allergy, Immunology and Dermatology, Hanoi Medical University, Hanoi, Vietnam. ³⁶³Cardiovascular Research Department, Methodist Hospital, Merrillville, IL, USA. ³⁶⁴Department of Surgery, Danang Family Hospital, Danang, Vietnam. ³⁶⁵Department of General Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. ³⁶⁶International Islamic University Islamabad, Islamabad, Pakistan. ³⁶⁷Department of Applied Microbiology, Oslo University Hospital, Taiz, Yemen. ³⁶⁸Faculty of Applied Sciences and Technology, Universiti Tun Hussein Onn Malaysia, Johor, Malaysia. ³⁶⁹Department of Applied Economics and Quantitative Analysis, University of Bucharest, Bucharest, Romania. ³⁷⁰School of Pharmacy, University of the Western Cape, Cape Town, South Africa. ³⁷¹Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. ³⁷²Department of Psychiatry, University of Lagos, Lagos, Nigeria. ³⁷³Slum and Rural Health Initiative Research Academy, Slum and Rural Health Initiative, Ibadan, Nigeria. ³⁷⁴Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria. ³⁷⁵Geography Department, East Carolina University, Greenville, NC, USA. ³⁷⁶Department of Pharmacotherapy and Pharmaceutical Care, Medical University of Warsaw, Warsaw, Poland. ³⁷⁷School of Medicine, Western Sydney University, Campbelltown, NSW, Australia. ³⁷⁸Department of Optometry and Vision Science, University of KwaZulu-Natal, KwaZulu-Natal, South Africa. ³⁷⁹Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia. ³⁸⁰Department of Medicine, University of Ibadan, Ibadan, Nigeria. ³⁸¹Department of Medicine, University College Hospital, Ibadan, Nigeria. ³⁸²Department of Forensic Medicine and Toxicology, Kasturba Medical College, Mangalore, Mangalore, India. ³⁸³Privatpraxis, Heidelberg, Germany. ³⁸⁴Global Health Governance Programme, University of Edinburgh, Edinburgh, UK. ³⁸⁵School of Dentistry, University of Leeds, Leeds, UK. ³⁸⁶Department of Genetics, Yale University, New Haven, CT, USA. ³⁸⁷Department of Development Studies, International Institute for Population Sciences, Mumbai, India. ³⁸⁸Department of Zoology, Yadava College, Madurai, India. ³⁸⁹Department of Zoology, Annai Fathima College, Madurai, India. ³⁹⁰Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania. ³⁹¹Medical School, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. ³⁹²Department of Maternal and Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil. ³⁹³Department of Neonatology, Case Western Reserve University, Cleveland, OH, USA. ³⁹⁴Manipal TATA Medical College, Manipal Academy of Higher Education, Manipal, India. ³⁹⁵Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh. ³⁹⁶Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA. ³⁹⁷Department of Community Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry, India. ³⁹⁸Department Biological Sciences, King Abdulaziz University, Jeddah, Egypt. ³⁹⁹Department of Protein Research, Research and Academic Institution, Alexandria, Egypt. ⁴⁰⁰Health Economics Research Centre, University of Oxford, Oxford, UK. ⁴⁰¹Department of Pharmacology and Toxicology, University of Antioquia, Medellin, Colombia. ⁴⁰²Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. ⁴⁰³Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. ⁴⁰⁴Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁰⁵Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates. ⁴⁰⁶Multidisciplinary Laboratory Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan. ⁴⁰⁷International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan. ⁴⁰⁸Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁰⁹Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴¹⁰Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran. ⁴¹¹Sharjah Institute of Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ⁴¹²Clinical Sciences Department, Sharjah, United Arab Emirates. ⁴¹³Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ⁴¹⁴Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ⁴¹⁵Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁴¹⁶Ludwig Maximilian University of Munich, Munich, Germany. ⁴¹⁷Institute for Employment Research, Nuremberg, Germany. ⁴¹⁸College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. ⁴¹⁹Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. ⁴²⁰Department of Neurology, Charité University Medical Center Berlin, Berlin, Germany. ⁴²¹Department of Neurology, University of Southern Denmark, Odense, Denmark. ⁴²²School of Public Health, Taipei Medical University, Taipei, Taiwan. ⁴²³Department of Entomology, Ain Shams University, Cairo, Egypt. ⁴²⁴Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo, Egypt. ⁴²⁵Market Access, Bayer, Istanbul, Türkiye. ⁴²⁶Faculty of Dentistry, AIMST University, Bedong, Malaysia. ⁴²⁷Department of Medicine and Surgery, Government Doon Medical College, Dehradun, India. ⁴²⁸National Heart, Lung, and Blood Institute, National Institute of Health, Rockville, MD, USA. ⁴²⁹Department of Clinical Sciences, Al-Quds University, Ajman, United Arab Emirates. ⁴³⁰Independent Consultant, Karachi, Pakistan. ⁴³¹Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia. ⁴³²National Institute of Infectious Diseases, Tokyo, Japan. ⁴³³Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Sokoto, Nigeria. ⁴³⁴Department of International Studies, Non-Communicable Diseases Research Center, Tehran, Iran. ⁴³⁵Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ⁴³⁶Department of Medical-Surgical Nursing, Mazandaran University of Medical Sciences, Sari, Iran. ⁴³⁷Department of Nursing and Health Sciences, Flinders University, Adelaide, Australia. ⁴³⁸Department of Pediatrics and Child Health Nursing, Dilla University, Dilla, Ethiopia. ⁴³⁹Unit of Basic Medical Sciences, University of Khartoum, Khartoum, Sudan. ⁴⁴⁰Department of Medical Microbiology and Infectious Diseases, Erasmus University, Rotterdam, Netherlands. ⁴⁴¹Family, Health Promotion, and Life Course Department, Pan American Health Organization, Bogota, Colombia. ⁴⁴²School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ⁴⁴³Department of Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA. ⁴⁴⁴Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India. ⁴⁴⁵Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA. ⁴⁴⁶Directive Board, Association of Licensed Optometry Professionals, Linda-a-Velha, Portugal. ⁴⁴⁷Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia. ⁴⁴⁸Department of Pharmacology, Shaqra University, Shaqra, Saudi Arabia. ⁴⁴⁹Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁴⁵⁰Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁵¹Aier Eye Hospital, Jinan University, Guangzhou, China. ⁴⁵²Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia. ⁴⁵³Faculty of Public Health, Universitas Sam Ratulangi, Manado, Indonesia. ⁴⁵⁴Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. ⁴⁵⁵Department of Public Health, Woldia University, Woldia, Ethiopia. ⁴⁵⁶Department of Medicine, University of Crete, Heraklion, Greece. ⁴⁵⁷Medical School, University of Crete, Heraklion, Greece. ⁴⁵⁸Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, India. ⁴⁵⁹Department of Public Health, East Carolina University, Greenville, NC, USA. ⁴⁶⁰College of Public Health, Temple University, Philadelphia, PA, USA. ⁴⁶¹Medical Genomics Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ⁴⁶²Department of Life Sciences, University of Management and Technology, Lahore, Pakistan. ⁴⁶³Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran. ⁴⁶⁴Department of Microbiology,

Islamic Azad University, Tehran, Iran. ⁴⁶⁵Urmia University of Medical Sciences, Urmia, Iran. ⁴⁶⁶Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA. ⁴⁶⁷Department of Epidemiology and Biostatistics, Bahir Dar University, Bahir Dar, Ethiopia. ⁴⁶⁸Department of Community Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka. ⁴⁶⁹Department of Ophthalmology Research, Queen Mamohato Memorial Hospital, Maseru, Lesotho. ⁴⁷⁰Ophthalmology Unit, Bahir Dar University, Bahir Dar, Ethiopia. ⁴⁷¹Department of Microbiology and Immunology, Zagazig University, Zagazig, Egypt. ⁴⁷²Department of Cells and Tissues, Molecular Biology Institute of Barcelona, Barcelona, Spain. ⁴⁷³Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, AB, Canada. ⁴⁷⁴Department of Oncology, University of Calgary, Calgary, AB, Canada. ⁴⁷⁵China Center for Health Development Studies, Peking University, Beijing, China. ⁴⁷⁶Center for the Study of Aging and Human Development, Duke University, Durham, NC, USA. ⁴⁷⁷Department of Health Management, Süleyman Demirel Üniversitesi (Süleyman Demirel University), Isparta, Türkiye. ⁴⁷⁸Department of Pharmacology, Bahir Dar University, Bahir Dar, Ethiopia. ⁴⁷⁹Pharmacy Department, Alkan Health Science Business and Technology College, Bahir Dar, Ethiopia. ⁴⁸⁰Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan. ⁴⁸¹Department of Public Health, Juntendo University, Tokyo, Japan. ⁴⁸²Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. ⁴⁸³Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. ⁴⁸⁴Department of Public Health, Dilla University, Dilla, Ethiopia. ⁴⁸⁵School of Medicine, Wuhan University, Wuhan, China. ⁴⁸⁶College of Traditional Chinese Medicine, Hebei University, Baoding, China. ⁴⁸⁷Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Warsaw, Poland. ⁴⁸⁸Department of Nursing, Yasuj University of Medical Sciences, Yasuj, Iran.